

CITATION REPORT

List of articles citing

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

DOI: 10.1126/science.1187659
Science, 2010, 329, 856-61.

Source: <https://exaly.com/paper-pdf/49674289/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1495	.		
1494	Human T helper cells specific for HIV reverse transcriptase: possible role in intrastructural help for HIV envelope-specific antibodies. 1995 , 25, 1217-23		16
1493	Therapeutic antibodies in HIV treatment--classical approaches to novel advances. 2010 , 16, 3754-66		6
1492	Broadly neutralizing antibodies and their significance for HIV-1 vaccines. 2010 , 8, 602-12		9
1491	HIV-1 (co)receptors: implications for vaccine and therapy design. 2010 , 16, 3701-15		3
1490	Structure-based vaccine design in HIV: blind men and the elephant?. 2010 , 16, 3744-53		40
1489	Antibody epitope exposure and neutralization of HIV-1. 2010 , 16, 3729-43		16
1488	Strategies for eliciting HIV-1 inhibitory antibodies. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 421-7	4.2	27
1487	Is developing an HIV-1 vaccine possible?. <i>Current Opinion in HIV and AIDS</i> , 2010 , 5, 362-7	4.2	24
1486	Inhibition of HIV-1 entry: multiple keys to close the door. 2010 , 5, 1825-35		15
1485	Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies. 2010 , 5, 1907-18		6
1484	Induction of immunity to human immunodeficiency virus type-1 by vaccination. 2010 , 33, 542-54		214
1483	From vaccines to memory and back. 2010 , 33, 451-63		390
1482	Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. 2010 , 17, 1486-91		72
1481	Pushing the envelope on HIV-1 neutralization. 2010 , 28, 929-31		5
1480	Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. 2010 , 16, 1117-9		112
1479	The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. 2010 , 16, 981-9		36

1478	Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. 2010 , 10, 527-35		120
1477	A renaissance for HIV vaccines?. 2010 , 10, 542-542		
1476	HIV/AIDS: vaccines and alternate strategies for treatment and prevention. 2010 , 1205 Suppl 1, E1-9		4
1475	Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. 2010 , 207, 2003-17		88
1474	On the growing complexity of HIV-1 vaccines. 2010 , 4, 543-552		
1473	Chemie. 2010 , 58, 994-997		
1472	GPI-anchored single chain Fv--an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. 2010 , 7, 79		24
1471	Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. 2010 , 403, 131-147		60
1470	LINCing chromatin remodeling to metastasis. 2010 , 28, 931-2		7
1469	Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. <i>Science</i> , 2010 , 329, 811-7	33.3	871
1468	AIDS/HIV. A boost for HIV vaccine design. <i>Science</i> , 2010 , 329, 770-3	33.3	61
1467	The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. <i>Journal of Virology</i> , 2011 , 85, 4828-40	6.6	348
1466	Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults. 2011 , 27, 557-567		20
1465	Moving ahead an HIV vaccine: use both arms to beat HIV. 2011 , 17, 1194-5		37
1464	Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120. 2011 , 50, 2769-79		0
1463	Vaccinology: precisely tuned antibodies nab HIV. 2011 , 477, 416-7		19
1462	Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. <i>Journal of Virology</i> , 2011 , 85, 8954-67	6.6	177
1461	Designing the next generation of vaccines for global public health. 2011 , 15, 545-66		51

1460	Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. 2011 , 208, 2599-606		161
1459	No acquisition: a new ambition for HIV vaccine development?. 2011 , 1, 246-53		11
1458	Broad neutralization coverage of HIV by multiple highly potent antibodies. 2011 , 477, 466-70		1164
1457	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.6	342
1456	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. <i>Journal of Virology</i> , 2011 , 85, 11502-19	6.6	148
1455	Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. <i>Journal of Virology</i> , 2011 , 85, 5262-74	6.6	74
1454	Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. 2011 , 50, 2756-68		5
1453	Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. <i>Science</i> , 2011 , 333, 1593-602	33.3	688
1452	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. 2011 , 17, 108-16		35
1451	Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. 2011 , 405, 284-97		51
1450	Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. 2011 , 414, 460-76		17
1449	The cost-effectiveness of a modestly effective HIV vaccine in the United States. <i>Vaccine</i> , 2011 , 29, 6113-24	4.1	21
1448	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. <i>Vaccine</i> , 2011 , 29, 4903-12	4.1	35
1447	Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. <i>Vaccine</i> , 2011 , 29, 5313-21	4.1	17
1446	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. <i>Vaccine</i> , 2011 , 29, 5250-9	4.1	28
1445	The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. <i>Vaccine</i> , 2011 , 29, 6107-12	4.1	17
1444	Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. <i>Vaccine</i> , 2011 , 29, 6191-218	4.1	78
1443	Modeling the impact of RV144-like vaccines on HIV transmission. <i>Vaccine</i> , 2011 , 29, 6069-71	4.1	10

1442	Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development. <i>Vaccine</i> , 2011 , 29, 6903-10	4.1	10
1441	Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. <i>Vaccine</i> , 2011 , 29, 9064-74	4.1	29
1440	Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. <i>Science</i> , 2011 , 333, 1633-7	33.3	874
1439	Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. 2011 , 118, 348-57		88
1438	The next decade of vaccines: societal and scientific challenges. 2011 , 378, 348-59		55
1437	HIV Envelope-Specific Antibody and Vaccine Efficacy. 2011 ,		1
1436	HIV-1 Glycoprotein Immunogenicity. 2011 ,		
1435	Grand Challenges in the Immunology of HIV and AIDS. <i>Frontiers in Immunology</i> , 2011 , 2, 20	8.4	2
1434	Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. <i>PLoS ONE</i> , 2011 , 6, e16074	3.7	69
1433	Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. <i>PLoS ONE</i> , 2011 , 6, e16857	3.7	74
1432	HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. <i>PLoS ONE</i> , 2011 , 6, e18233	3.7	30
1431	Dual neonate vaccine platform against HIV-1 and <i>M. tuberculosis</i> . <i>PLoS ONE</i> , 2011 , 6, e20067	3.7	25
1430	A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. <i>PLoS ONE</i> , 2011 , 6, e20927	3.7	14
1429	Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). <i>PLoS ONE</i> , 2011 , 6, e21339	3.7	27
1428	Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. <i>PLoS ONE</i> , 2011 , 6, e24078	3.7	88
1427	Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. <i>PLoS ONE</i> , 2011 , 6, e27098	3.7	8
1426	Editorial neuroAIDS review. 2011 , 25, 123-41		63
1425	Épidémiologie, transmission et prévention de l'infection VIH. 2011 , 8, 1-10		

1424	Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. 2011 , 25, 1249-64		7
1423	Thirty years of HIV and AIDS: future challenges and opportunities. 2011 , 154, 766-71		113
1422	A 2020 vision for vaccines against HIV, tuberculosis and malaria. 2011 , 473, 463-9		206
1421	Single B cell antibody technologies. 2011 , 28, 453-7		46
1420	Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. <i>Virology</i> , 2011 , 409, 163-74	3.6	18
1419	A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. <i>Virology</i> , 2011 , 418, 123-32	3.6	15
1418	The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. <i>Virology</i> , 2011 , 421, 235-44	3.6	17
1417	Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications. 2011 , 9, 212		5
1416	HIV vaccine: hopes and hurdles. 2011 , 16, 948-56		5
1415	A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. <i>Science</i> , 2011 , 334, 1097-103	33.3	576
1414	Prospects for an HIV vaccine: leading B cells down the right path. 2011 , 18, 1317-21		35
1413	Alterations of the B-cell response by HIV-1 replication. 2011 , 8, 23-30		29
1412	Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. 2011 , 9, 40		6
1411	Sensitivity to electrical stimulation of human immunodeficiency virus type 1 and MAGIC-5 cells. 2011 , 1, 23		4
1410	Limitations to the structure-based design of HIV-1 vaccine immunogens. 2011 , 24, 741-53		34
1409	HIV-1: from escapism to conservatism. 2011 , 41, 3390-3		12
1408	Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. 2011 , 34, 269-80		235
1407	Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. 2011 , 23, 383-90		79

1406	High throughput cellular screens to interrogate the human T and B cell repertoires. 2011 , 23, 430-5		16
1405	Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. <i>Journal of Virology</i> , 2011 , 85, 2524-35	6.6	40
1404	AIDS/HIV. Converging on an HIV vaccine. <i>Science</i> , 2011 , 333, 1589-90	33.3	12
1403	Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F. 2011 , 27, 889-901		11
1402	HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. 2011 , 27, 877-87		46
1401	Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus. <i>Journal of Virology</i> , 2011 , 85, 12811-4	6.6	11
1400	Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. <i>Journal of Virology</i> , 2011 , 85, 5825-39	6.6	87
1399	Progress in the rational design of an AIDS vaccine. 2011 , 366, 2759-65		47
1398	The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. <i>Journal of Virology</i> , 2011 , 85, 5252-61	6.6	41
1397	Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. <i>Journal of Virology</i> , 2011 , 85, 8217-26	6.6	74
1396	Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency. <i>Journal of Virology</i> , 2011 , 85, 6814-8	6.6	11
1395	Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. <i>Journal of Virology</i> , 2011 , 85, 11401-8	6.6	75
1394	Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. <i>Journal of Virology</i> , 2011 , 85, 6906-12	6.6	64
1393	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. 2011 , 208, 439-54		87
1392	Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. <i>Journal of Virology</i> , 2011 , 85, 7236-45	6.6	45
1391	Rational design of a meningococcal antigen inducing broad protective immunity. 2011 , 3, 91ra62		118
1390	Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. <i>Journal of Virology</i> , 2011 , 85, 9039-50	6.6	44
1389	Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. <i>Journal of Virology</i> , 2011 , 85, 4927-36	6.6	10

1388	Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. 2011 , 1, a007278		114
1387	The prevention of infection-associated cancers. 2011 , 32, 787-95		67
1386	Vaccine design reaches the atomic level. 2011 , 3, 91ps29		4
1385	Can HIV p24 be a suitable scaffold for presenting Env antigens?. 2011 , 18, 2003-4		4
1384	Vaccinology: A sweet cleft in HIVs armour. 2011 , 480, 324-5		9
1383	Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. 2011 , 286, 14531-41		45
1382	A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. 2011 , 3, 402-7		9
1381	Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. <i>Journal of Virology</i> , 2011 , 85, 8467-76	6.6	11
1380	HIV infection and specific mucosal immunity: workshop 4B. 2011 , 23, 142-51		3
1379	Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy. 2011 , 58, 359-62		11
1378	Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. <i>Journal of Virology</i> , 2011 , 85, 6687-701	6.6	101
1377	HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. <i>Journal of Virology</i> , 2011 , 85, 1077-85	6.6	17
1376	Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. 2011 , 286, 33511-9		18
1375	Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. <i>Journal of Virology</i> , 2011 , 85, 8514-27	6.6	100
1374	Designed oligomers of cyanovirin-N show enhanced HIV neutralization. 2011 , 108, 14079-84		31
1373	Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. 2011 , 108, 11440-5		139
1372	Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. 2011 , 92, 247-68		119
1371	Increasing the potency and breadth of an HIV antibody by using structure-based rational design. <i>Science</i> , 2011 , 334, 1289-93	33.3	307

1370	Antibody evasion by a gammaherpesvirus O-glycan shield. <i>PLoS Pathogens</i> , 2011 , 7, e1002387	7.6	32
1369	Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. <i>Journal of Virology</i> , 2011 , 85, 4578-85	6.6	42
1368	Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. <i>PLoS Pathogens</i> , 2011 , 7, e1002002	7.6	31
1367	epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. <i>Journal of Virology</i> , 2011 , 85, 9286-99	6.6	24
1366	[Evolution and Diversity of HIV-1]. 2011 , 100, 29-35		1
1365	"Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. <i>PLoS Pathogens</i> , 2011 , 7, e1002095	7.6	12
1364	Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. <i>PLoS Pathogens</i> , 2011 , 7, e1002209	7.6	104
1363	Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. <i>PLoS Pathogens</i> , 2011 , 7, e1002442	7.6	32
1362	Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. <i>Journal of Virology</i> , 2011 , 85, 7719-29	6.6	50
1361	Cross-reactive broadly neutralizing antibodies: timing is everything. <i>Frontiers in Immunology</i> , 2012 , 3, 215	8.4	23
1360	Controlling the HIV/AIDS epidemic: current status and global challenges. <i>Frontiers in Immunology</i> , 2012 , 3, 250	8.4	19
1359	Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1248-57	7	34
1358	Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. <i>PLoS Pathogens</i> , 2012 , 8, e1002634	7.6	156
1357	A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade. 2012 , 287, 11942-50		7
1356	Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. 2012 , 13, 5674-99		21
1355	Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. 2012 , 19, 1027-37		17
1354	HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. <i>PLoS Pathogens</i> , 2012 , 8, e1002611	7.6	51
1353	Structure-based design for high-hanging vaccine fruits. 2012 , 114, 33-50		6

1352	Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin 47 . <i>PLoS Pathogens</i> , 2012 , 8, e1002686	7.6	120
1351	Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. <i>PLoS Pathogens</i> , 2012 , 8, e1002797	7.7	170
1350	Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. <i>Journal of Virology</i> , 2012 , 86, 11521-32	6.6	294
1349	Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. <i>PLoS ONE</i> , 2012 , 7, e35083	3.7	35
1348	A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. <i>Journal of Virology</i> , 2012 , 86, 12472-83	6.6	43
1347	Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. <i>Journal of Virology</i> , 2012 , 86, 2488-500	6.6	38
1346	HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. 2012 , 109, 12111-6		141
1345	Enhanced HIV-1 neutralization by antibody heterologation. 2012 , 109, 875-80		49
1344	Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization. 2012 , 93, 1495-1505		7
1343	PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. <i>Journal of Virology</i> , 2012 , 86, 4394-403	6.6	98
1342	BlyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. 2012 , 188, 6018-26		25
1341	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. 2012 , 109, E2083-90		168
1340	Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. <i>Journal of Virology</i> , 2012 , 86, 9566-82	6.6	23
1339	A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. <i>Journal of Virology</i> , 2012 , 86, 8319-23	6.6	70
1338	Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. 2012 , 109, 18921-5		376
1337	Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B-infected former plasma donors from China naive to antiretroviral therapy. 2012 , 93, 2267-2278		18
1336	Single-chain Fv-based anti-HIV proteins: potential and limitations. <i>Journal of Virology</i> , 2012 , 86, 195-202	6.6	25
1335	DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. 2012 , 8, 1630-7		5

1334	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. 2012 , 209, 1091-103		71
1333	Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity. 2012 , 13, 523-9		57
1332	Human B-cell ontogeny in humanized NOD/SCID β (null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. 2012 , 13, 399-410		27
1331	A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. 2012 , 287, 43170-9		25
1330	HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. <i>Journal of Virology</i> , 2012 , 86, 7496-507	6.6	67
1329	HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. <i>Journal of Virology</i> , 2012 , 86, 3393-7	6.6	60
1328	Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. 2012 , 109, E3268-77		409
1327	High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , 2012 , 86, 2153-64	6.6	51
1326	Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. <i>Journal of Virology</i> , 2012 , 86, 12105-14	6.6	24
1325	Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. 2012 , 287, 5673-86		49
1324	Monoclonal antibody-based candidate therapeutics against HIV type 1. 2012 , 28, 425-34		12
1323	HIV: Design by trial. 2012 , 490, 350-1		
1322	HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. <i>Journal of Virology</i> , 2012 , 86, 3574-87	6.6	75
1321	A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. <i>Journal of Virology</i> , 2012 , 86, 10857-61	6.6	26
1320	UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. <i>Journal of Virology</i> , 2012 , 86, 4989-99	6.6	30
1319	Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. 2012 , 56, 4310-9		37
1318	OX40 facilitates control of a persistent virus infection. <i>PLoS Pathogens</i> , 2012 , 8, e1002913	7.6	51
1317	CD4 binding determinant mimicry for HIV vaccine design. <i>Frontiers in Immunology</i> , 2012 , 3, 383	8.4	5

1316	Basic research in HIV vaccinology is hampered by reductionist thinking. <i>Frontiers in Immunology</i> , 2012 , 3, 194	8.4	49
1315	Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. <i>Journal of Virology</i> , 2012 , 86, 8750-64	6.6	55
1314	Anti-HIV B Cell lines as candidate vaccine biosensors. 2012 , 189, 4816-24		48
1313	HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. 2012 , 56, 4257-67		26
1312	The Antibody Response against HIV-1. 2012 , 2, a007039		122
1311	Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. <i>Journal of Virology</i> , 2012 , 86, 5014-25	6.6	11
1310	Current understanding in HIV immunopathology and treatment. 2012 , 105, 725-8		
1309	The design and evaluation of HIV-1 vaccines. 2012 , 26, 1293-302		35
1308	Potent and broadly neutralizing antibodies targeting HIV envelope protein gp120. 2012 , 7, 225-227		1
1307	Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. 2012 , 120, 4571-82		67
1306	Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. <i>Journal of Virology</i> , 2012 , 86, 12676-85	6.6	37
1305	Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. <i>Virology</i> , 2012 , 432, 505-10	3.6	78
1304	Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. <i>Journal of Virology</i> , 2012 , 86, 13152-63	6.6	20
1303	Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. 2012 , 63, 113-30		48
1302	Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. <i>Journal of Virology</i> , 2012 , 86, 12115-28	6.6	22
1301	Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations. 2012 , 18, 4517-27		12
1300	Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. 2012 , 37, 412-25		364
1299	High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. 2012 , 386, 117-23		132

1298	Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. 2012 , 13, 2549-57		26
1297	Omics-Based Systems Vaccinology for Vaccine Target Identification. 2012 , 73, 559-568		9
1296	Structure and design of broadly-neutralizing antibodies against HIV. 2012 , 34, 231-7		5
1295	Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. 2012 , 42, 1055-62		10
1294	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. <i>Virology</i> , 2012 , 433, 410-20	3.6	2
1293	Characterization of human IgG repertoires in an acute HIV-1 infection. 2012 , 93, 399-407		17
1292	Vaccine applications of flow cytometry. 2012 , 57, 383-91		24
1291	Macrophage internal HIV-1 is protected from neutralizing antibodies. <i>Journal of Virology</i> , 2012 , 86, 2826-36		64
1290	Exploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic. 2012 , 22, 6099-102		2
1289	Colloidal graphenes as heterogeneous additives to enhance protein crystal yield. 2012 , 4, 5321-4		8
1288	HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. <i>Journal of Virology</i> , 2012 , 86, 11231-41	6.6	51
1287	Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. <i>Journal of Virology</i> , 2012 , 86, 5844-56	6.6	69
1286	Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in <i>Daphne gnidium</i> . 2012 , 75, 414-9		41
1285	HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. <i>Vaccine</i> , 2012 , 30, 4310-5	4.1	46
1284	Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV. <i>Vaccine</i> , 2012 , 30, 607-13	4.1	6
1283	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. <i>Vaccine</i> , 2012 , 30, 922-30	4.1	23
1282	Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. <i>Vaccine</i> , 2012 , 30, 1911-6	4.1	22
1281	Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. <i>Vaccine</i> , 2012 , 30, 4135-43	4.1	16

1280	Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. <i>Journal of Virology</i> , 2012 , 86, 8516-26	6.6	41
1279	Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. 2012 , 19, 893-9		130
1278	Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. <i>Journal of Virology</i> , 2012 , 86, 13434-44	6.6	62
1277	Gene therapy as a vaccine for HIV-1. 2012 , 12, 1315-21		8
1276	Tools to therapeutically harness the human antibody response. 2012 , 12, 709-19		108
1275	Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. 2012 , 425, 931-7		5
1274	HIV vaccine design: the neutralizing antibody conundrum. 2012 , 24, 316-23		22
1273	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. 2012 , 492, 118-22		401
1272	A Blueprint for HIV Vaccine Discovery. 2012 , 12, 396-407		302
1271	A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C. 2012 , 12, 87		13
1270	MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. 2012 , 9, 36		17
1269	HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. 2012 , 9, 76		27
1268	Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors. 2012 , 9, 196		5
1267	Increased titers of neutralizing antibodies after immunization with both envelope proteins of the porcine endogenous retroviruses (PERVs). 2012 , 9, 260		23
1266	Structural and genetic basis for development of broadly neutralizing influenza antibodies. 2012 , 489, 566-70		188
1265	B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. 2012 , 30, 423-33		351
1264	Plant made anti-HIV microbicides--a field of opportunity. 2012 , 30, 1614-26		11
1263	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. 2012 , 20, 532-9		54

1262	Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. 2012 , 386, 85-93		56
1261	Antibody-based protection against HIV infection by vectored immunoprophylaxis. 2011 , 481, 81-4		407
1260	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. 2012 , 482, 89-93		391
1259	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. 2012 , 491, 406-12		624
1258	Candidate antibody-based therapeutics against HIV-1. 2012 , 26, 143-62		11
1257	Molecular biology of HIV: implications for new therapies. 2012 , 25-43		
1256	The immune response to HIV. 2012 , 45-57		
1255	The design of a global HIV vaccine. 2012 , 97-112		
1254	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. 2012 , 209, 1469-79		131
1253	The development of CD4 binding site antibodies during HIV-1 infection. <i>Journal of Virology</i> , 2012 , 86, 7588-95	6.6	105
1252	Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. <i>Journal of Virology</i> , 2012 , 86, 4688-92	6.6	132
1251	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. 2012 , 109, 5663-8		200
1250	High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. 2012 , 4, 142ra96		86
1249	Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. <i>PLoS ONE</i> , 2012 , 7, e30233	3.7	11
1248	Isolation of monoclonal antibodies with predetermined conformational epitope specificity. <i>PLoS ONE</i> , 2012 , 7, e38943	3.7	10
1247	Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject. <i>PLoS ONE</i> , 2012 , 7, e39534	3.7	20
1246	A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. <i>PLoS ONE</i> , 2012 , 7, e41235	3.7	15
1245	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. <i>PLoS ONE</i> , 2012 , 7, e41936	3.7	65

1244	HIV p24 as scaffold for presenting conformational HIV Env antigens. <i>PLoS ONE</i> , 2012 , 7, e43318	3.7	6
1243	Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. <i>PLoS ONE</i> , 2012 , 7, e44241	3.7	21
1242	Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm. <i>PLoS ONE</i> , 2012 , 7, e51633	3.7	11
1241	Interplay between HIV-1 and Host Genetic Variation: A Snapshot into Its Impact on AIDS and Therapy Response. 2012 , 2012, 508967		1
1240	Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics. 2012 , 3, 315		53
1239	Monkey vaccine hints at how to stop HIV. 2012 ,		
1238	Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. 2012 , 21, 1-11		6
1237	Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120. 2012 , 8, 1858-66		4
1236	The changing face of HIV vaccine research. 2012 , 15, 17407		37
1235	Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. <i>Science</i> , 2012 , 337, 183-6	33.3	334
1234	Efficient on-chip isolation of HIV subtypes. 2012 , 12, 1508-15		63
1233	Lessons learned from HIV-1 vaccine trials: new priorities and directions. 2012 , 13, 423-7		70
1232	The structural biology of HIV-1: mechanistic and therapeutic insights. 2012 , 10, 279-90		203
1231	Polyreactive antibodies in adaptive immune responses to viruses. 2012 , 69, 1435-45		81
1230	HIV-1 virus-like particles produced by stably transfected <i>Drosophila</i> S2 cells: a desirable vaccine component. <i>Journal of Virology</i> , 2012 , 86, 7662-76	6.6	28
1229	Neutralizing antibodies and control of HIV: moves and countermoves. 2012 , 9, 64-72		19
1228	Sustained release of proteins from high water content supramolecular polymer hydrogels. 2012 , 33, 4646-52		128
1227	Vaccines for the future: learning from human immunology. 2012 , 5, 149-55		38

1226	Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. <i>Virology</i> , 2012 , 426, 34-41	3.6	27
1225	The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant. <i>Virology</i> , 2012 , 427, 25-33	3.6	22
1224	Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. <i>Virology</i> , 2012 , 427, 198-207	3.6	74
1223	Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. <i>Virology</i> , 2012 , 428, 121-7	3.6	43
1222	Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. 2012 , 157, 1-20		42
1221	Development of prophylactic vaccines against HIV-1. 2013 , 10, 72		56
1220	Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. 2013 , 10, 3		33
1219	Closing the door to human immunodeficiency virus. 2013 , 4, 86-102		13
1218	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. 2013 , 39, 245-58		254
1217	An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. 2013 , 14, 93-103		131
1216	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. 2013 , 13, 693-701		255
1215	Advances in antiviral vaccine development. 2013 , 255, 230-42		68
1214	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160 β (BaL.). 2013 , 397, 47-54		8
1213	Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. <i>Journal of Virology</i> , 2013 , 87, 7218-33	6.6	93
1212	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. 2013 , 110, 16538-43		208
1211	Designing tomorrow's vaccines. 2013 , 368, 551-60		199
1210	Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. 2013 , 31, 1047-52		37
1209	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. 2013 , 503, 224-8		489

1208	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. 2013 , 503, 277-80		359
1207	Past, present and future: 30 years of HIV research. 2013 , 11, 877-83		176
1206	Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 Å crystal structure of gp120 and M48U1. <i>Structure</i> , 2013 , 21, 1018-29	5.2	27
1205	Antibodies in HIV-1 vaccine development and therapy. <i>Science</i> , 2013 , 341, 1199-204	33.3	361
1204	HIV virology, testing and monitoring. 2013 , 41, 420-424		3
1203	HIV-1 neutralizing antibodies: understanding nature's pathways. 2013 , 254, 225-44		368
1202	Immunogenetics of HIV disease. 2013 , 254, 245-64		106
1201	The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?. 2013 , 10, 103		25
1200	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. 2013 , 10, 102		37
1199	Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. 2013 , 11, 165		8
1198	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. 2013 , 10, 347		12
1197	Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. 2013 , 10, 147		2
1196	Isolation of human monoclonal antibodies from peripheral blood B cells. 2013 , 8, 1907-15		94
1195	Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. <i>Vaccine</i> , 2013 , 31, 5422-9	4.1	24
1194	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. 2013 , 110, 6049-54		45
1193	Vaccines based on structure-based design provide protection against infectious diseases. 2013 , 12, 1301-11		17
1192	Broadly neutralizing antibodies against HIV-1: templates for a vaccine. <i>Virology</i> , 2013 , 435, 46-56	3.6	88
1191	Antibody gene transfer for HIV immunoprophylaxis. 2013 , 14, 1-5		34

1190	Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies. 2013 , 110, 1422-7		11
1189	Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. 2013 , 425, 444-56		52
1188	Isothermal titration calorimetry vs. high performance liquid chromatography fingerprint. 2013 , 111, 965-970		
1187	F(ab) ₂ fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. 2013 , 15, 887-94		3
1186	Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. <i>Vaccine</i> , 2013 , 31, 5789-97	4.1	58
1185	HIV-1 envelope glycoprotein structure. 2013 , 23, 268-76		63
1184	Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display. 2013 , 60, 27-37		40
1183	Immunogenicity and safety of the vaccinia virus LC16m8 vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol. <i>Vaccine</i> , 2013 , 31, 3549-57	4.1	13
1182	Hepatitis C virus vaccines in the era of new direct-acting antivirals. 2013 , 7, 171-85		9
1181	Harnessing CD4+ T cell responses in HIV vaccine development. 2013 , 19, 143-9		75
1180	Neutralizing antibodies to HIV-1 induced by immunization. 2013 , 210, 209-23		127
1179	Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. <i>Journal of Virology</i> , 2013 , 87, 4985-93	6.6	18
1178	Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. 2013 , 153, 126-38		376
1177	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. 2013 , 496, 469-76		759
1176	Broadly neutralizing antiviral antibodies. 2013 , 31, 705-42		351
1175	HIV: Roadmaps to a vaccine. 2013 , 496, 441-2		25
1174	Imaging: Magnetic bacteria on a diamond plate. 2013 , 496, 442-3		1
1173	Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. <i>Virology</i> , 2013 , 439, 81-8	3.6	17

1172	Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. 2013 , 43, 499-509		14
1171	Rational HIV immunogen design to target specific germline B cell receptors. <i>Science</i> , 2013 , 340, 711-6	33.3	519
1170	Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy. <i>PLoS ONE</i> , 2013 , 8, e63537	3.7	28
1169	Inadequate T follicular cell help impairs B cell immunity during HIV infection. 2013 , 19, 494-9		286
1168	Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. 2013 , 7, 4733-45		129
1167	Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. 2013 , 499, 102-6		481
1166	Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. 2013 , 110, 6470-5		119
1165	Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. 2013 , 254, 207-24		113
1164	Advances in structure-based vaccine design. 2013 , 3, 322-31		71
1163	Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. <i>Science</i> , 2013 , 340, 751-6	33.3	172
1162	Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. 2013 , 13, 657-71		20
1161	Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. 2013 , 20, 804-13		219
1160	Catching HIV in the act with 3D electron microscopy. 2013 , 21, 397-404		18
1159	Novel HIV vaccine strategies: overview and perspective. 2013 , 1, 99-112		22
1158	Human immunodeficiency virus vaccines. 2013 , 1097-1121		0
1157	A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. 2013 , 57, 745-55		11
1156	Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. <i>Journal of Virology</i> , 2013 , 87, 10447-59	6.6	34
1155	A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. <i>Journal of Virology</i> , 2013 , 87, 10232-43	6.6	23

1154	Rational design of membrane proximal external region lipopeptides containing chemical modifications for HIV-1 vaccination. 2013 , 20, 39-45		16
1153	A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. <i>PLoS Pathogens</i> , 2013 , 9, e1003202	7.6	52
1152	The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. <i>PLoS Pathogens</i> , 2013 , 9, e1003754	7.6	144
1151	Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. <i>PLoS Pathogens</i> , 2013 , 9, e1003106	7.6	141
1150	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. <i>PLoS Pathogens</i> , 2013 , 9, e1003738	7.6	147
1149	Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. 2013 , 110, 18220-5		56
1148	Increased functional stability and homogeneity of viral envelope spikes through directed evolution. <i>PLoS Pathogens</i> , 2013 , 9, e1003184	7.6	36
1147	Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. <i>PLoS Pathogens</i> , 2013 , 9, e1003477	7.6	43
1146	Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in <i>Nicotiana benthamiana</i> plants and utility of VRC01 in combination microbicides. 2013 , 57, 2076-86		31
1145	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. 2013 , 110, 13540-5		63
1144	Progress in HIV-1 vaccine development. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 326-32	4.2	42
1143	Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 382-92	4.2	23
1142	New paradigms for functional HIV-specific nonneutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2013 , 8, 393-401	4.2	56
1141	Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). 2013 , 1, 67-80		4
1140	Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. <i>Journal of Virology</i> , 2013 , 87, 8535-44	6.6	20
1139	Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. <i>Journal of Virology</i> , 2013 , 87, 10163-72	6.6	39
1138	Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility. <i>Journal of Virology</i> , 2013 , 87, 1884-9	6.6	58
1137	Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. <i>Journal of Virology</i> , 2013 , 87, 9233-49	6.6	10

1136	HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. <i>Journal of Virology</i> , 2013 , 87, 7191-6	6.6	24
1135	Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. <i>Journal of Virology</i> , 2013 , 87, 4882-94	6.6	55
1134	Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. <i>Journal of Virology</i> , 2013 , 87, 10173-81	6.6	18
1133	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. 2013 , 110, 18214-9		65
1132	Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. <i>Journal of Virology</i> , 2013 , 87, 187-98	6.6	19
1131	Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies. 2013 , 288, 9815-9825		24
1130	Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes. <i>Journal of Virology</i> , 2013 , 87, 5372-83	6.6	48
1129	Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein. <i>Journal of Virology</i> , 2013 , 87, 8798-804	6.6	12
1128	Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. <i>Journal of Virology</i> , 2013 , 87, 11604-16	6.6	38
1127	IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2013 , 4, 373	8.4	16
1126	Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. <i>Journal of Virology</i> , 2013 , 87, 10855-73	6.6	25
1125	Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals. 2013 , 78, 357-70		2
1124	Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. <i>Journal of Virology</i> , 2013 , 87, 9547-57	6.6	40
1123	Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study. 2013 , 9, 462-70		11
1122	Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. 2013 , 110, 10598-603		82
1121	De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. 2013 , 110, E4088-97		80
1120	Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. <i>Journal of Virology</i> , 2013 , 87, 10047-58	6.6	54
1119	A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. 2013 , 5, 946-55		18

1118	Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. 2013 , 110, 12438-43		85
1117	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. 2013 , 210, 1235-49		76
1116	Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. 2013 , 9, 2253-62		35
1115	Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. 2013 , 210, 655-63		220
1114	Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. <i>Journal of Virology</i> , 2013 , 87, 13239-51	6.6	53
1113	Linking genotype to phenotype on beads: high throughput selection of peptides with biological function. 2013 , 3, 3030		5
1112	Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. 2013 , 62, 1-9		47
1111	Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. 2013 , 27, 337-46		15
1110	Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups. 2013 , 27, 1239-44		8
1109	The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. 2013 , 27, 2529-39		9
1108	HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. 2013 , 27, 1535-44		16
1107	Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. 2013 , 11, 378-87		69
1106	Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. <i>PLoS ONE</i> , 2013 , 8, e52732	3.7	15
1105	N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. <i>PLoS ONE</i> , 2013 , 8, e55701	3.7	31
1104	Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. <i>PLoS ONE</i> , 2013 , 8, e75665	3.7	189
1103	Detection of HIV-1 neutralizing antibodies in a human CD4+/CXCR4+/CCR5+ T-lymphoblastoid cell assay system. <i>PLoS ONE</i> , 2013 , 8, e77756	3.7	31
1102	HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo. <i>PLoS ONE</i> , 2013 , 8, e84234	3.7	22
1101	Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity. <i>PLoS ONE</i> , 2013 , 8, e66638	3.7	8

1100	Secondary mechanisms of diversification in the human antibody repertoire. <i>Frontiers in Immunology</i> , 2013 , 4, 42	8.4	22
1099	Multiantibody strategies for HIV. 2013 , 2013, 632893		6
1098	HIV trial under scrutiny. 2013 , 493, 279-80		7
1097	Trial, Error, and Breakthrough: A Review of HIV Vaccine Development. 2014 , 05,		5
1096	Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. <i>PLoS ONE</i> , 2014 , 9, e86905	3.7	18
1095	Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. <i>PLoS ONE</i> , 2014 , 9, e97478	3.7	27
1094	Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization. <i>PLoS ONE</i> , 2014 , 9, e98060	3.7	5
1093	Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. <i>PLoS ONE</i> , 2014 , 9, e100598	3.7	20
1092	Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design. <i>PLoS ONE</i> , 2014 , 9, e104674	3.7	3
1091	A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development. <i>PLoS ONE</i> , 2014 , 9, e109196	3.7	5
1090	High-throughput sequencing of human immunoglobulin variable regions with subtype identification. <i>PLoS ONE</i> , 2014 , 9, e111726	3.7	22
1089	Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. <i>PLoS ONE</i> , 2014 , 9, e112268	3.7	33
1088	An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses. <i>PLoS ONE</i> , 2014 , 9, e115047	3.7	4
1087	MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. <i>PLoS ONE</i> , 2014 , 9, e116153	3.7	24
1086	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. 2014 , 2, 1-14		20
1085	Nanomagnet-Based Detoxifying Machine: An Alternative/Complementary Approach in HIV therapy. 2014 , 05,		12
1084	Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. 2014 , 124, 3252-62		91
1083	The Pursuit of a HIV Vaccine [Trials, Challenges and Strategies. 2014 , 05,		

1082	Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. 2014 , 111, E738-47		63
1081	Highly parallel characterization of IgG Fc binding interactions. 2014 , 6, 915-27		48
1080	Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. <i>Journal of Virology</i> , 2014 , 88, 9538-52	6.6	28
1079	Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1. 2014 , 289, 34780-800		18
1078	Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. 2014 , 6, 236ra63		148
1077	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. 2014 , 29, 299-307		5
1076	Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice. 2014 , 15, 40		48
1075	HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1. 2014 , 289, 20526-42		18
1074	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. 2014 , 111, 17624-9		239
1073	Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. <i>Frontiers in Immunology</i> , 2014 , 5, 250	8.4	69
1072	An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. <i>Frontiers in Immunology</i> , 2014 , 5, 593	8.4	18
1071	Passive immunization against HIV/AIDS by antibody gene transfer. 2014 , 6, 428-47		11
1070	Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. 2014 , 6, 5047-76		5
1069	Which Antibody Functions are Important for an HIV Vaccine?. <i>Frontiers in Immunology</i> , 2014 , 5, 289	8.4	41
1068	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. 2014 , 6, 243ra88		189
1067	HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization. <i>PLoS Pathogens</i> , 2014 , 10, e1004337	7.6	21
1066	Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. <i>PLoS Pathogens</i> , 2014 , 10, e1004271	7.6	41
1065	Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1. <i>PLoS Pathogens</i> , 2014 , 10, e1004552	7.6	23

1064	Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitoretal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2014 , 5, 202	8.4	10
1063	Immunity to HIV in Early Life. <i>Frontiers in Immunology</i> , 2014 , 5, 391	8.4	54
1062	Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. <i>PLoS Pathogens</i> , 2014 , 10, e1004461	7.6	44
1061	HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. 2014 , 11, e1001616		28
1060	The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques. <i>Journal of Virology</i> , 2014 , 88, 21-40	6.6	13
1059	An intravaginal ring for the sustained delivery of antibodies. 2014 , 103, 3611-3620		27
1058	Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. 2014 , 142, 1-23		35
1057	Large-scale analysis of somatic hypermutations in antibodies reveals which structural regions, positions and amino acids are modified to improve affinity. 2014 , 281, 306-19		33
1056	Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. 2014 , 6, 577-618		5
1055	HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile. 2014 , 30, 1089-98		6
1054	Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence. 2014 , 30, 1001-5		3
1053	HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. <i>Science</i> , 2014 , 346, 1380-1383	33.3	94
1052	HIV. Expanding the breadth of an HIV-1 vaccine. <i>Science</i> , 2014 , 346, 1290-1	33.3	
1051	Targeting Cellular Cofactors in HIV Therapy. 2014 , 183-222		6
1050	Neutralisation of HIV-1 cell-cell spread by human and llama antibodies. 2014 , 11, 83		29
1049	Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits. 2014 , 11, 125		9
1048	Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers. 2014 , 67, 472-80		4
1047	Recent progress in HIV vaccines inducing mucosal immune responses. 2014 , 28, 1701-18		12

1046	Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. 2014 , 66, 473-83		33
1045	Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. 2014 , 28, 2201-11		4
1044	Adeno-associated virus delivery of broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2014 , 9, 250-6	4.2	22
1043	Association between HIV-1 coreceptor usage and resistance to broadly neutralizing antibodies. 2014 , 67, 107-12		9
1042	Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. <i>Current Opinion in HIV and AIDS</i> , 2014 , 9, 263-70	4.2	28
1041	Broadly neutralizing antibodies and the promise of universal vaccines: where are we now?. 2014 , 6, 51-7		8
1040	NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences. 2014 , 42, W64-71		14
1039	Mucosal immunity in the female genital tract, HIV/AIDS. 2014 , 2014, 350195		40
1038	Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes. <i>Journal of Virology</i> , 2014 , 88, 10975-81	6.6	9
1037	Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. <i>Journal of Virology</i> , 2014 , 88, 10177-88	6.6	53
1036	Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. 2014 , 40, 657-68		286
1035	Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. 2014 , 15, 644-51		45
1034	Persistence of VRC01-resistant HIV-1 during antiretroviral therapy. 2014 , 57, 88-96		2
1033	10E8-like neutralizing antibodies against HIV-1 induced using a precisely designed conformational peptide as a vaccine prime. 2014 , 57, 117-27		6
1032	Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. 2014 , 192, 1100-1106		73
1031	Emerging concepts on T follicular helper cell dynamics in HIV infection. 2014 , 35, 278-86		32
1030	Human immunodeficiency virus antibodies and the vaccine problem. 2014 , 275, 444-55		6
1029	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. 2014 , 509, 55-62		537

1028	Profiling the IgOme: meeting the challenge. 2014 , 588, 318-25		11
1027	Distinct advancements and challenges in HIV 1 vaccine development and cure review. 2014 , 13, 1-5		3
1026	The past, present and future of neutralizing antibodies for hepatitis C virus. 2014 , 105, 100-11		95
1025	bNAber: database of broadly neutralizing HIV antibodies. 2014 , 42, D1133-9		61
1024	Rapid production of HIV-1 neutralizing antibodies in baculovirus infected insect cells. 2014 , 99, 87-93		2
1023	Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. 2014 , 159, 15-22		6
1022	Early development of broadly neutralizing antibodies in HIV-1-infected infants. 2014 , 20, 655-8		123
1021	Protein engineering strategies for the development of viral vaccines and immunotherapeutics. 2014 , 588, 298-307		12
1020	Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. <i>Virology</i> , 2014 , 448, 363-74	3.6	7
1019	Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. <i>Journal of Virology</i> , 2014 , 88, 1125-39	6.6	44
1018	Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. 2014 , 12, 300-11		32
1017	Recent strategies targeting HIV glycans in vaccine design. 2014 , 10, 990-9		82
1016	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. 2014 , 211, 2061-74		245
1015	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. <i>Journal of Virology</i> , 2014 , 88, 12669-82	6.6	198
1014	Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. <i>Journal of Virology</i> , 2014 , 88, 13910-7	6.6	34
1013	Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. <i>Journal of Virology</i> , 2014 , 88, 2489-507	6.6	201
1012	Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. <i>Journal of Virology</i> , 2014 , 88, 12949-67	6.6	29
1011	A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. 2014 , 289, 29912-26		25

1010	Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. <i>Journal of Virology</i> , 2014 , 88, 2645-57	6.6	55
1009	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. 2014 , 16, 304-13		99
1008	Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. <i>Virology</i> , 2014 , 462-463, 115-25	3.6	20
1007	Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner. <i>Virology</i> , 2014 , 462-463, 266-72	3.6	1
1006	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. <i>Virology</i> , 2014 , 462-463, 363-76	3.6	16
1005	Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2014 , 88, 12968-81	6.6	44
1004	Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography. <i>Journal of Virology</i> , 2014 , 88, 12265-75	6.6	7
1003	Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. <i>Vaccine</i> , 2014 , 32, 4916-24	4.1	7
1002	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 2014 , 514, 642-5		232
1001	New pharmacological strategies to fight enveloped viruses. 2014 , 35, 470-8		23
1000	Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. 2014 , 11, 41		121
999	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. 2014 , 11, 23		22
998	Designer antigens for elicitation of broadly neutralizing antibodies against HIV. 2014 , 3, e24		1
997	Antibody B cell responses in HIV-1 infection. 2014 , 35, 549-61		72
996	Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method. 2014 , 15, 77		7
995	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. 2014 , 11, 32		7
994	Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. 2014 , 11, 42		14
993	Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. 2014 , 192, 3637-44		46

992	A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. 2014 , 143, 13-20		102
991	Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. <i>Journal of Virology</i> , 2014 , 88, 14002-16	6.6	28
990	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. 2014 , 515, 138-42		330
989	Structural insights on the role of antibodies in HIV-1 vaccine and therapy. 2014 , 156, 633-48		268
988	The maturation of antibody technology for the HIV epidemic. 2014 , 92, 570-7		5
987	Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. 2014 , 7, 785-95		180
986	Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein. 2014 , 192, 5802-12		4
985	Immunogen design for HIV-1 and influenza. 2014 , 1844, 1891-1906		20
984	Vector-Mediated In Vivo Antibody Expression. 2014 , 2, AID-0016-2014		9
983	Antibodies: Computer-Aided Prediction of Structure and Design of Function. 2014 , 2,		14
982	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. 2014 , 28, 163-9		254
981	Antibody engineering for increased potency, breadth and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 151-9	4.2	33
980	HIV broadly neutralizing antibody targets. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 135-43	4.2	91
979	Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis. 2015 , 6, e01375-15		21
978	The HIV glycan shield as a target for broadly neutralizing antibodies. 2015 , 282, 4679-91		83
977	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. 2015 , 3, 82-93		8
976	Antibodies Targeting the Envelope of HIV-1. 2015 , 3, AID-0025-2014		9
975	Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining. 2015 , 5, 13926		38

974	Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an Fc β 11a independent mechanism and do not diminish cytokines production. 2014 , 4, 5845		10
973	Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes. 2015 , 226, 15-24		6
972	The HAND Database: a gateway to understanding the role of HIV in HIV-associated neurocognitive disorders. 2015 , 8, 70		7
971	Discrete partitioning of HIV-1 Env forms revealed by viral capture. 2015 , 12, 81		12
970	Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques. 2015 , 44, 275-85		2
969	N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03. 2015 , 69, 270-7		14
968	Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. 2015 , 182, 289-301		177
967	Vectored antibody gene delivery for the prevention or treatment of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 190-7	4.2	26
966	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. 2015 , 7, 5443-75		20
965	Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies. <i>PLoS ONE</i> , 2015 , 10, e0117227	3.7	8
964	Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. <i>PLoS ONE</i> , 2015 , 10, e0120648	3.7	4
963	Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01. <i>PLoS ONE</i> , 2015 , 10, e0120847	3.7	10
962	Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. <i>PLoS ONE</i> , 2015 , 10, e0125575	3.7	10
961	A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. <i>PLoS ONE</i> , 2015 , 10, e0125581	3.7	13
960	Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies. <i>PLoS ONE</i> , 2015 , 10, e0126428	3.7	8
959	Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. <i>PLoS ONE</i> , 2015 , 10, e0128562	3.7	7
958	The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection. <i>PLoS Pathogens</i> , 2015 , 11, e1004973	7.6	24
957	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. <i>PLoS Pathogens</i> , 2015 , 11, e1005238	7.6	36

956	HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions. 2015 , 2015, 560347		13
955	Receptor binding domain based HIV vaccines. 2015 , 2015, 594109		4
954	DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. <i>Journal of Virology</i> , 2015 , 89, 4158-69	6.6	29
953	Therapy of Viral Infections. 2015 ,		4
952	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. <i>Journal of Virology</i> , 2015 , 89, 5318-29	6.6	86
951	Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. 2015 , 11, 63-9		60
950	Passive Immunization. 2015 , 1403-1434		9
949	Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers". 2015 , 118, 1-9		11
948	HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. 2015 , 19, 765-83		28
947	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. 2015 , 161, 1280-92		219
946	Adenovirus-Vectored Broadly Neutralizing Antibodies Directed Against gp120 Prevent Human Immunodeficiency Virus Type 1 Acquisition in Humanized Mice. 2015 , 26, 622-34		5
945	Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies. 2016 , 26, 251-60		13
944	HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. 2015 , 2, 1464-77		36
943	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. 2015 , 7, 319ra206		308
942	Engineering and exploitation of a fluorescent HIV-1 gp120 for live cell CD4 binding assays. <i>Virology</i> , 2015 , 476, 240-248	3.6	4
941	Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV. 2015 , 73, 169-79		6
940	Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection. <i>Virology</i> , 2015 , 475, 179-86	3.6	6
939	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. 2015 , 6, 6144		101

938	Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. 2015 , 160, 785-797		125
937	HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. <i>Journal of Virology</i> , 2015 , 89, 4201-13	6.6	90
936	Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals. 2015 , 194, 2561-8		12
935	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. 2015 , 519, 87-91		211
934	Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. 2015 , 29, 70-80		1
933	Intra-spike crosslinking overcomes antibody evasion by HIV-1. 2015 , 160, 433-46		84
932	Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. <i>Journal of Virology</i> , 2015 , 89, 2659-71	6.6	101
931	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. 2015 , 23, 204-11		63
930	Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion. <i>Journal of Virology</i> , 2015 , 89, 2966-71	6.6	12
929	Should all research subjects be treated the same?. 2015 , 45, 17-20		2
928	Complex Fluids and Soft Structures in the Human Body. 2015 , 53-110		11
927	Resurfaced fluorescent protein as a sensing platform for label-free detection of copper(II) ion and acetylcholinesterase activity. <i>Analytical Chemistry</i> , 2015 , 87, 1974-80	7.8	87
926	CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. 2015 , 96, 1899-905		7
925	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015 , 11, e1004932	7.6	116
924	HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015 , 349, 156-61	33.3	264
923	Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01. 2015 , 61, 262-71		5
922	HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. <i>Science</i> , 2015 , 349, 191-5	33.3	91
921	Prospects for a globally effective HIV-1 vaccine. <i>Vaccine</i> , 2015 , 33 Suppl 4, D4-12	4.1	24

920	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. <i>Journal of Virology</i> , 2015 , 89, 9090-102	6.6	9
919	SOFT ROBOTICS. A 3D-printed, functionally graded soft robot powered by combustion. <i>Science</i> , 2015 , 349, 161-5	33.3	608
918	Almighty antibodies? A new wave of antibody-based approaches aims to combat HIV. 2015 , 21, 657-9		3
917	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. 2015 , 22, 522-31		254
916	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. 2015 , 161, 1505-15		197
915	Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. <i>PLoS Pathogens</i> , 2015 , 11, e1004570	7.6	78
914	Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. 2015 , 6, 6565		59
913	Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization. 2015 , 194, 5903-14		21
912	Antibody responses to envelope glycoproteins in HIV-1 infection. 2015 , 16, 571-6		304
911	Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate. 2015 , 290, 9195-208		9
910	Vector-mediated antibody gene transfer for infectious diseases. 2015 , 848, 149-67		8
909	A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. 2015 , 31, 1126-38		8
908	Viral receptor-binding site antibodies with diverse germline origins. 2015 , 161, 1026-1034		114
907	Strategies to guide the antibody affinity maturation process. 2015 , 11, 137-47		59
906	Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. <i>Journal of Virology</i> , 2015 , 89, 6952-9	6.6	31
905	Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes. <i>Journal of Virology</i> , 2015 , 89, 6725-45	6.6	20
904	Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics. 2015 , 214, 46-53		13
903	Gene Therapy for HIV and Chronic Infections. 2015 ,		

902	Eliminating antibody polyreactivity through addition of N-linked glycosylation. 2015 , 24, 1019-30		8
901	The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies. 2015 , 441-461		
900	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. 2015 , 161, 470-485		177
899	Computational tools for epitope vaccine design and evaluation. 2015 , 11, 103-12		46
898	Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. <i>Journal of Virology</i> , 2015 , 89, 894-907	6.6	37
897	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 5895-903	6.6	82
896	Workshop report: Malaria vaccine development in Europe--preparing for the future. <i>Vaccine</i> , 2015 , 33, 6137-44	4.1	5
895	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. 2015 , 6, 8167		62
894	Immune correlates of vaccine protection against HIV-1 acquisition. 2015 , 7, 310rv7		142
893	A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. <i>Journal of Virology</i> , 2015 , 89, 2507-19	6.6	33
892	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. <i>Journal of Virology</i> , 2015 , 89, 10383-98	6.6	105
891	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. 2015 , 162, 1090-100		181
890	Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. 2015 , 6, 8443		36
889	Activation and lysis of human CD4 cells latently infected with HIV-1. 2015 , 6, 8447		73
888	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 8334-45	6.6	81
887	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. <i>Journal of Virology</i> , 2015 , 89, 9485-98	6.6	5
886	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. <i>Journal of Virology</i> , 2015 , 89, 12501-12	6.6	67
885	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. 2015 , 21, 1065-70		416

884	Stabilization of Outer Domain of gp120 from HIV-1 Subtype C for Vaccine Immunogen Design. 2015 , 9, 6-15		2
883	Phenotypic Correlates of HIV-1 Macrophage Tropism. <i>Journal of Virology</i> , 2015 , 89, 11294-311	6.6	40
882	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. 2015 , 6,		19
881	A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS. 2015 , 290, 19780-95		19
880	Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising. 2015 , 112, 11654-9		44
879	Injectable and implantable antiretroviral strategies for HIV prevention. 2015 , 10, 1163-1176		9
878	Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. 2015 , 11, 539-50		145
877	Prospects for a Globally Effective HIV-1 Vaccine. 2015 , 49, S307-18		10
876	Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region. <i>Virology</i> , 2015 , 486, 187-97	3.6	6
875	Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. 2015 , 83, 771-80		24
874	Combinatorial library-based profiling of the antibody response against hepatitis C virus in humans. 2015 , 96, 52-63		4
873	Polyreactivity and autoreactivity among HIV-1 antibodies. <i>Journal of Virology</i> , 2015 , 89, 784-98	6.6	123
872	Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. 2015 , 8, 316-26		18
871	Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium. 2015 , 31, 36-44		19
870	Broad Neutralizing Antibodies to HIV Env and Other Complex Viral Antigens from Vaccinated Cows. 2016 , 07,		2
869	Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory. 2016 , 17,		29
868	Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. 2016 , 17,		12
867	Structural basis for germline antibody recognition of HIV-1 immunogens. 2016 , 5,		48

866	Antiviral Vaccines: Challenges and Advances. 2016 , 283-310		5
865	Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. 2016 , 4,		13
864	Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2016 , 7, 391	8.4	6
863	Learning the Relationship between the Primary Structure of HIV Envelope Glycoproteins and Neutralization Activity of Particular Antibodies by Using Artificial Neural Networks. 2016 , 17,		9
862	Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. <i>PLoS ONE</i> , 2016 , 11, e0157353	3.7	7
861	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005520	7.6	106
860	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016 , 12, e1005537	7.6	39
859	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. <i>PLoS Pathogens</i> , 2016 , 12, e1005815	7.6	76
858	Advances and hope for perinatal HIV remission and cure in children and adolescents. 2016 , 28, 86-92		14
857	Structural analysis of nested neutralizing and non-neutralizing B cell epitopes on ricin toxins enzymatic subunit. 2016 , 84, 1162-72		14
856	Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120. 2016 , 132, 252-61		5
855	Passive immunization with HIV-1-neutralizing antibodies: is it effective and safe?. 2016 , 22, 460-2		
854	Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. 2016 , 7, 12040		86
853	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. 2016 , 7, 12041		101
852	Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity. <i>Journal of Virology</i> , 2016 , 90, 8875-90	6.6	12
851	Immunoregulatory functions of immune complexes in vaccine and therapy. 2016 , 8, 1120-1133		36
850	Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. 2016 , 129, 55-107		7
849	First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. 2016 , 13, 82		16

848	Clonify: unseeded antibody lineage assignment from next-generation sequencing data. 2016 , 6, 23901		35
847	Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. 2016 , 6, 39462		15
846	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. 2016 , 14, 97-111		29
845	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. 2016 , 55, 2197-213		19
844	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. 2016 , 44, 939-50		62
843	Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. <i>Vaccine</i> , 2016 , 34, 2444-2452	4.1	3
842	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. 2016 , 213, 469-81		210
841	Humoral Immune Pressure Selects for HIV-1 CXCR4-chemokine Receptor 4-using Variants. 2016 , 8, 237-247		12
840	Exploiting Mucosal Immunity for Antiviral Vaccines. 2016 , 34, 575-608		62
839	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2016 , 90, 6999-7006	6.6	57
838	Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. 2016 , 44, 1215-26		102
837	The Cloning and Expression of Human Monoclonal Antibodies: Implications for Allergen Immunotherapy. 2016 , 16, 15		6
836	Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers. <i>Journal of Virology</i> , 2015 , 90, 2806-17	6.6	89
835	Intact glycopeptide characterization using mass spectrometry. 2016 , 13, 513-22		46
834	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. <i>Journal of Virology</i> , 2016 , 90, 6127-6139	6.6	86
833	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 2016 , 196, 3064-78		42
832	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016 , 352, 997-1001	33.3	202
831	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016 , 90, 5899-5914	6.6	45

830	Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry. 2016 , 291, 13088-97		21
829	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. 2016 , 3, 122-134		53
828	Identifying possible sites for antibody neutralization escape: Implications for unique functional properties of the C-terminal tail of Human Immunodeficiency Virus Type 1 gp41. 2016 , 175, 21-30		0
827	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016 , 352, 828-33	33.3	218
826	Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. 2016 , 8, 1156-66		6
825	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. 2016 , 34, 635-59		366
824	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. 2016 , 27, 2372-2385		38
823	Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. <i>Journal of Virology</i> , 2016 , 90, 10220-10235	6.6	21
822	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016 , 353, 1557-1560	33.3	106
821	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. 2016 , 166, 1459-1470.e1178		1178
820	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. 2016 , 166, 1445-1458.e12		204
819	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. 2016 , 166, 1471-1484.e18		132
818	The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2016 , 90, 10642-10659	6.6	10
817	Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing. 2016 , 5, e93		28
816	Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. <i>Vaccine</i> , 2016 , 34, 5344-5351	4.1	10
815	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , 2016 , 90, 10574-10586	6.6	19
814	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. <i>Structure</i> , 2016 , 24, 1346-1357	5.2	29
813	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. <i>Journal of Virology</i> , 2016 , 90, 9224-36	6.6	22

812	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. <i>Journal of Virology</i> , 2016 , 90, 7822-32	6.6	13
811	Smart Materials for DNA-Based Nanoconstructions. 2016 , 21-60		
810	Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. <i>Journal of Virology</i> , 2016 , 90, 9712-9724	6.6	56
809	Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. 2016 , 7, 13473		77
808	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. 2016 , 3, 16068		41
807	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. 2016 , 23, 906-915		143
806	Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India. <i>Virology</i> , 2016 , 499, 105-113	3.6	6
805	IgG subclass co-expression brings harmony to the quartet model of murine IgG function. 2016 , 94, 949-954		55
804	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. <i>Journal of Virology</i> , 2016 , 90, 10362-10378	6.6	15
803	A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. 2016 , 45, 31-45		97
802	VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice. 2016 , 161, 2449-55		23
801	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. 2016 , 13, 48		17
800	HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98. 2016 , 45, 958-960		7
799	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. 2016 , 375, 2037-2050		276
798	Utility of Hydrogen Exchange Mass Spectrometry in Epitope Mapping. 2016 , 247-263		3
797	An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. 2016 , 197, 3982-3998		12
796	Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. 2016 , 6, 36298		21
795	Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. 2016 , 17, 1560-1570		20

794	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. 2016 , 22, 1465-1469	73
793	HIV-host interactome revealed directly from infected cells. 2016 , 1, 16068	33
792	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. 2016 , 80, 989-1010	55
791	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. 2016 , 12, 196-207	28
790	HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation. 2016 , 6, 20987	3
789	Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans. 2016 , 6, 36339	4
788	The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa. 2016 , 197, 3841-3849	11
787	HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. 2016 , 13, 60	19
786	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. 2016 , 13, 62	31
785	Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. 2016 , 13, 81	7
784	Castasterone assisted accumulation of polyphenols and antioxidant to increase tolerance of B. juncea plants towards copper toxicity. 2016 , 2,	5
783	Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. 2016 , 73, 365-373	10
782	Novel approaches in preclinical HIV vaccine research. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 601-606 4.2	2
781	The first 24 h: targeting the window of opportunity for antibody-mediated protection against HIV-1 transmission. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 561-568 4.2	7
780	Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. 2016 , 30, 2551-2553	5
779	Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities. 2016 , 11, 357-62	7
778	New concepts in HIV-1 vaccine development. 2016 , 41, 39-46	58
777	Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. 2016 , 42, 56-64	21

776	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. <i>Journal of Virology</i> , 2016 , 90, 813-28	6.6	30
775	Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. 2016 , 165, 1621-1631		129
774	HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. 2016 , 166, 77-87		92
773	Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies. 2016 , 13, 8		26
772	T follicular regulatory cells. 2016 , 271, 246-59		215
771	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. <i>Science</i> , 2016 , 353, 179-84	33.3	314
770	The Diversity and Molecular Evolution of B-Cell Receptors during Infection. 2016 , 33, 1147-57		48
769	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. 2016 , 15, 349-65		38
768	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. 2016 , 22, 362-8		134
767	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. <i>Science</i> , 2016 , 351, 1458-63	33.3	266
766	Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction. 2016 , 26, 4-20		19
765	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. <i>Journal of Virology</i> , 2016 , 90, 5231-5245	6.6	17
764	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. 2016 , 196, 3729-43		24
763	Construction and characterization of HIV type 1 CRF07_BC infectious molecular clone from men who have sex with men. 2016 , 229, 70-7		3
762	Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. <i>Journal of Virology</i> , 2016 , 90, 3446-57	6.6	26
761	Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective. 2016 , 44, 90-110		5
760	Norovirus vaccines: Correlates of protection, challenges and limitations. 2016 , 12, 1653-69		12
759	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. 2016 , 37, 221-232		78

758	Engineering broadly neutralizing antibodies for HIV prevention and therapy. 2016 , 103, 157-173		13
757	Broadly Neutralizing Antibodies for HIV Eradication. 2016 , 13, 31-7		62
756	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. 2016 , 165, 449-63	209	
755	Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. <i>Journal of Virology</i> , 2016 , 90, 4017-4031	6.6	19
754	Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies. 2016 , 8, 338-46		80
753	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016 , 90, 4951-4965	6.6	21
752	Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting. 2016 , 161, 789-99		4
751	Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. 2016 , 60, 437-50		4
750	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. 2016 , 23, 81-90		126
749	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016 , 90, 1321-32	6.6	57
748	The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 2016 , 9, 414-27		12
747	Microscale Technologies for High-Throughput Analysis of Immune Cells. 2016 , 219-230		
746	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. <i>Journal of Virology</i> , 2016 , 90, 829-41	6.6	18
745	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016 , 90, 76-91	6.6	151
744	Microscale Technologies for Cell Engineering. 2016 ,		3
743	Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. 2016 , 33, 189-210		1
742	The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. <i>Journal of Virology</i> , 2017 , 91,	6.6	32
741	IgG Fc variant cross-reactivity between human and rhesus macaque FcBs. 2017 , 9, 455-465		14

740	B-cell responses to HIV infection. 2017 , 275, 33-48		85
739	Identification and specificity of broadly neutralizing antibodies against HIV. 2017 , 275, 11-20		155
738	HIV antibodies for treatment of HIV infection. 2017 , 275, 313-323		46
737	Use of broadly neutralizing antibodies for HIV-1 prevention. 2017 , 275, 296-312		101
736	Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. 2017 , 275, 108-128		26
735	Germline-targeting immunogens. 2017 , 275, 203-216		62
734	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. 2017 , 275, 145-160		102
733	Survivors Remorse: antibody-mediated protection against HIV-1. 2017 , 275, 271-284		23
732	Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. 2017 , 275, 89-107		24
731	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). 2017 , 27, 707-719		19
730	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. 2017 , 7, 40800		7
729	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. 2017 , 23, 185-191		282
728	Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. 2017 , 8,		22
727	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017 , 91,	6.6	61
726	Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs. <i>Journal of Virology</i> , 2017 , 91,	6.6	49
725	Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region. <i>Virology</i> , 2017 , 505, 113-126	3.6	10
724	Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. 2017 , 7, 948		16
723	B-cell abnormalities and impact on antibody response in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 203-208	4.2	8

722	Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. <i>Vaccine</i> , 2017 , 35, 3272-3278	4.1	5
721	In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. 2017 , 8, 15371		38
720	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017 , 91,	6.6	5
719	Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. 2017 , 61,		21
718	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. 2017 , 46, 777-791.e10		50
717	Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. 2017 , 7, 46557		6
716	Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies. 2017 , 53, 5453-5456		13
715	Dense Array of Spikes on HIV-1 Virion Particles. <i>Journal of Virology</i> , 2017 , 91,	6.6	35
714	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. 2017 , 19, 719-732		123
713	Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 343-350	4.2	22
712	Human IgG repertoire of malaria antigen-immunized human immune system (HIS) mice. 2017 , 188, 46-52		
711	Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. <i>Journal of Virology</i> , 2017 , 91,	6.6	25
710	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. <i>Journal of Infectious Diseases</i> , 2017 , 215, S160-S171	7	17
709	Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design. <i>Vaccine</i> , 2017 , 35, 3067-3075	4.1	2
708	Protein design: from computer models to artificial intelligence. 2017 , 7, e1318		15
707	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017 , 91,	6.6	32
706	Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI. 2017 , 7, 387-395		5
705	Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in <i>Pichia pastoris</i> . 2017 , 7, 70		11

704	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. 2017 , 9, 792-800		33
703	Adjuvants: tailoring humoral immune responses. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 278-284	4.2	15
702	How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 229-240	4.2	44
701	Progress in HIV-1 antibody research using humanized mice. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 285-293	4.2	10
700	Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. 2017 , 7, 45163		13
699	Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy. 2017 , 7, 46308		4
698	Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. <i>Virology</i> , 2017 , 505, 193-209	3.6	21
697	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. 2017 , 9,		59
696	Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. 2017 , 429, 930-947		47
695	Progress toward active or passive HIV-1 vaccination. 2017 , 214, 3-16		94
694	Effect of HIV-1 Env on SERINC5 Antagonism. <i>Journal of Virology</i> , 2017 , 91,	6.6	56
693	Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. 2017 , 9, 550-566		4
692	In silico methods for design of biological therapeutics. 2017 , 131, 33-65		36
691	An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies. 2017 , 7, 13779		16
690	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. 2017 , 13, 1115-1122		73
689	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , 2017 , 91,	6.6	12
688	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. 2017 , 249, 85-93		2
687	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017 , 358, 85-90	33.3	176

686	Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 2017 , 13, 2996-3009		6
685	Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. 2017 , 7, 8390		27
684	Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies. 2017 , 214, 2283-2302		23
683	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017 , 91,	6.6	16
682	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. <i>Journal of Virology</i> , 2017 , 91,	6.6	18
681	Potent NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017 , 91,	6.6	24
680	mRNA mediates passive vaccination against infectious agents, toxins, and tumors. 2017 , 9, 1434-1447		65
679	A streamlined cloning workflow minimising the time-to-strain pipeline for <i>Pichia pastoris</i> . 2017 , 7, 15817		4
678	Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry. <i>Virology</i> , 2017 , 512, 180-186.	6.6	7
677	A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01. 2017 , 33, 1248-1257		5
676	Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. 2017 , 4, 491-510		2
675	Fight fire with fire: Gene therapy strategies to cure HIV. 2017 , 15, 747-758		9
674	Construction of a recombinant full-length membrane associated IgG library. 2017 , 238, 156-163		4
673	Broadly neutralizing antibodies: An approach to control HIV-1 infection. 2017 , 36, 31-40		8
672	Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. <i>Virology</i> , 2017 , 501, 12-24	3.6	8
671	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. 2016 , 2, 16199		103
670	Global dynamics of an age-structured virus model with saturation effects. 2017 , 40, 1851-1864		6
669	Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. 2017 , 292, 278-291		11

668	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. 2017 , 64, 1098-1104		25
667	Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination. 2017 , 51, 819-829		1
666	Broadly Neutralizing Antibodies. 2017 , 3-21		2
665	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. 2017 , 9,		50
664	Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. <i>Frontiers in Immunology</i> , 2016 , 7, 661	8.4	8
663	Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. <i>Frontiers in Immunology</i> , 2017 , 8, 1025	8.4	14
662	Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2017 , 8, 1104	8.4	23
661	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. <i>Frontiers in Immunology</i> , 2017 , 8, 1154	8.4	22
660	CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children. <i>Frontiers in Immunology</i> , 2017 , 8, 1568	8.4	11
659	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017 , 8, 1802	8.4	58
658	Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem. 2017 , 134, 235-352		7
657	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017 , 13, e1006148	7.6	36
656	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. 2017 , 14, e1002435		71
655	Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model. 2017 , 15, e2001549		14
654	Prospects for passive immunity to prevent HIV infection. 2017 , 14, e1002436		18
653	The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. 2017 , 14, 50		14
652	Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor. 2017 , 8, 63047-63063		5
651	Three unrelated protease inhibitors enhance accumulation of pharmaceutical recombinant proteins in <i>Nicotiana benthamiana</i> . 2018 , 16, 1797-1810		39

650	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018 , 92,	6.6	119
649	Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses. <i>Journal of Virology</i> , 2018 , 92,	6.6	13
648	Rational design of a trisppecific antibody targeting the HIV-1 Env with elevated anti-viral activity. 2018 , 9, 877		43
647	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. 2018 , 93, 436-447		14
646	Distinct functions for the membrane-proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion. 2018 , 293, 6099-6120		8
645	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. 2018 , 9, 596-615		26
644	A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. 2018 , 24, 610-616		71
643	Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11. <i>Journal of Virology</i> , 2018 , 92,	6.6	12
642	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. 2018 , 4, 788-796		48
641	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. <i>Journal of Virology</i> , 2018 , 92,	6.6	22
640	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. 2018 , 22, 1798-1809		33
639	Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency. 2018 , 16, 1840007		3
638	Passive immunotherapy of viral infections: Isuper-antibodiesLenter the fray. 2018 , 18, 297-308		166
637	Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. <i>Journal of Virology</i> , 2018 , 92,	6.6	20
636	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. 2018 , 454, 48-58		10
635	The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. 2018 , 19, 206-224		122
634	Mechanism of HIV-1 Resistance to an Electronically Constrained β Helical Peptide Membrane Fusion Inhibitor. <i>Journal of Virology</i> , 2018 , 92,	6.6	11
633	Functional interrogation and mining of natively paired human V:V antibody repertoires. 2018 , 36, 152-155		80

632	Passive and active antibody studies in primates to inform HIV vaccines. 2018 , 17, 127-144		27
631	Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses. 2018 , 173, 1783-1795.e14		47
630	Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. <i>Journal of Virology</i> , 2018 , 92,	6.6	8
629	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. 2018 , 14, 2116-2127		14
628	Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 366-373	4.2	47
627	A systematic analysis of the expression of the anti-HIV VRC01 antibody in <i>Pichia pastoris</i> through signal peptide optimization. 2018 , 149, 43-50		9
626	eCD4-Ig Variants That More Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2018 , 92,	6.6	16
625	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. 2018 , 48, 500-513.e6		51
624	A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. 2018 , 24, 408-416		136
623	Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. 2018 , 243, 75-82		9
622	Microfluidic single-cell technology in immunology and antibody screening. 2018 , 59, 47-61		50
621	New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. 2018 , 69, 409-419		22
620	Castasterone confers copper stress tolerance by regulating antioxidant enzyme responses, antioxidants, and amino acid balance in <i>B. juncea</i> seedlings. 2018 , 147, 725-734		41
619	Impact of HIV-1 Envelope Conformation on ADCC Responses. 2018 , 26, 253-265		44
618	Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. <i>Journal of Virology</i> , 2018 , 92,	6.6	5
617	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018 , 92,	6.6	32
616	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. 2018 , 19, 20-28		66
615	Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. 2018 , 293, 830-846		10

614	Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains. 2018 , 32, 1917-1926		10
613	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. <i>PLoS ONE</i> , 2018 , 13, e0208345	3.7	4
612	Diffusion-Chemotaxis Model of Effects of Cortisol on Immune Response to Human Immunodeficiency virus. 2018 , 7, 207-227		2
611	Anti-HIV Passive Immunization in Animal Models. 2018 , 04,		1
610	Antibody-dependent cellular cytotoxicity in HIV infection. 2018 , 32, 2439-2451		37
609	Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. 2018 , 8, 16527		52
608	Antibody-mediated prevention and treatment of HIV-1 infection. 2018 , 15, 73		39
607	Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India. <i>Frontiers in Immunology</i> , 2018 , 9, 2841	8.4	4
606	HIV-1 vaccine design through minimizing envelope metastability. 2018 , 4, eaau6769		43
605	Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. 2018 , 10,		26
604	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1007431	7.6	20
603	Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. <i>PLoS ONE</i> , 2018 , 13, e0209437	3.7	5
602	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. 2018 , 25, 3123-3135.e6		17
601	Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan. 2018 , 8, 15031		13
600	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. 2018 , 49, 1162-1174.e8		32
599	Novel Strategies for Malaria Vaccine Design. <i>Frontiers in Immunology</i> , 2018 , 9, 2769	8.4	21
598	Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , 2018 , 9, 2613	8.4	3
597	Development of a Stable MGAT1 CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2018 , 9, 2313	8.4	2

596	Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. 2018 , 5, e723-e731		8
595	A Novel Neutralizing Antibody Specific to the DE Loop of VP1 Can Inhibit EV-D68 Infection in Mice. 2018 , 201, 2557-2569		8
594	Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1. 2018 , 15, 66		26
593	Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0. <i>Frontiers in Immunology</i> , 2018 , 9, 1621	8.4	3
592	HIV-1 inhibitory properties of eCD4-IgMim2 determined using an Env-mediated membrane fusion assay. <i>PLoS ONE</i> , 2018 , 13, e0206365	3.7	
591	Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. 2018 , 5, ofy242		17
590	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. <i>Frontiers in Immunology</i> , 2018 , 9, 2429	8.4	12
589	Recent progress in broadly neutralizing antibodies to HIV. 2018 , 19, 1179-1188		186
588	Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. 2018 , 7, 174		3
587	Display of the HIV envelope protein at the yeast cell surface for immunogen development. <i>PLoS ONE</i> , 2018 , 13, e0205756	3.7	5
586	HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins. 2018 , 13, 347-364		5
585	The expanding array of HIV broadly neutralizing antibodies. 2018 , 15, 70		24
584	When designing vaccines, consider the starting material: the human B cell repertoire. 2018 , 53, 209-216		44
583	Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. 2018 , 293, 15002-15020		7
582	Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. <i>Journal of Virology</i> , 2018 , 92,	6.6	16
581	The latest evidence for possible HIV-1 curative strategies. 2018 , 7, 212522		23
580	Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies. 2018 , 163, 3303-3315		6
579	Engineering multi-specific antibodies against HIV-1. 2018 , 15, 60		27

578	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. 2018 , 215, 1589-1608		23
577	Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. 2018 , 23, 2568-2581	25	
576	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. 2018 , 48, 855-871	18	0
575	HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. 2018 , 7,		76
574	Structure-based immunogen design-leading the way to the new age of precision vaccines. 2018 , 51, 163-169	16	
573	Therapeutic Antibody Discovery in Infectious Diseases Using Single-Cell Analysis. 2018 , 1068, 89-102	6	
572	Single Cell Biomedicine. 2018 ,		0
571	A single, continuous metric to define tiered serum neutralization potency against HIV. 2018 , 7,		11
570	HIV cure: global overview of bNAbs patents and related scientific publications. 2018 , 28, 551-560	2	
569	Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. 2018 , 31, 121-133		8
568	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018 , 14, e1006986	7.6	22
567	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. 2018 , 49, 301-311.e5		70
566	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. 2018 , 49, 288-300.e8		110
565	Hydroponic Treatment of with Kifunensine Modifies the -glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression. 2018 , 9, 62		11
564	Glycoengineering HIV-1 Env creates supercharged and hybrid glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018 , 14, e1007024	7.6	12
563	HIV Vaccines and Cure. 2018 ,		1
562	Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. <i>PLoS ONE</i> , 2018 , 13, e0196370	3.7	13
561	Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production. <i>PLoS ONE</i> , 2018 , 13, e0197656	3.7	10

560	Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design. <i>Frontiers in Immunology</i> , 2017 , 8, 2009	8.4	13
559	Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries. <i>Frontiers in Immunology</i> , 2018 , 9, 329	8.4	10
558	Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. <i>Frontiers in Immunology</i> , 2018 , 9, 618	8.4	2
557	5LRapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. <i>Frontiers in Immunology</i> , 2018 , 9, 628	8.4	11
556	Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?. 2018 , 2018, 8724549		15
555	Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice. <i>Journal of Virology</i> , 2018 , 92,	6.6	28
554	HIV Broadly Neutralizing Antibodies: VRC01 and Beyond. 2018 , 1075, 53-72		9
553	Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine. 2018 , 1075, 73-95		9
552	Long term stability of a HIV-1 neutralizing monoclonal antibody using isothermal calorimetry. 2018 , 554, 61-69		7
551	Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. 2018 , 15, 17		2
550	Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. <i>Vaccine</i> , 2018 , 36, 5166-5172	4.1	2
549	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. <i>PLoS Pathogens</i> , 2018 , 14, e1007238	7.6	9
548	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. 2018 , 462, 74-82		11
547	Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. <i>Vaccine</i> , 2018 , 36, 5671-5677	4.1	7
546	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. 2018 , 24, 857-867		169
545	HIV Env on Lockdown. 2018 , 23, 699-701		
544	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. 2018 , 15, e1002493		118
543	Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/BLenv molecular clones derived from infections in China. 2018 , 7, 90		2

542	Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. 2018 , 34, 794-803		10
541	HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. <i>Journal of Virology</i> , 2018 , 92,	6.6	14
540	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018 , 14, e1006860	7.6	42
539	Integrating linear optimization with structural modeling to increase HIV neutralization breadth. <i>PLoS Computational Biology</i> , 2018 , 14, e1005999	5	4
538	Human Immunodeficiency Virus Vaccines. 2018 , 400-429.e25		
537	Inaugural Editorial: Searching for Magic Bullets. 2018 , 1, 1-5		8
536	Immunoglobulin Clonotype and Ontogeny Inference. 2019 , 972-983		
535	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. 2019 , 178, 1004-1015.e14		16
534	Generation of porcine monoclonal antibodies based on single cell technologies. 2019 , 215, 109913		1
533	Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting. <i>PLoS ONE</i> , 2019 , 14, e0220986	3.7	
532	Delayed vaginal SHIV infection in VRC01 and anti-47 treated rhesus macaques. <i>PLoS Pathogens</i> , 2019 , 15, e1007776	7.6	11
531	Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. 2019 , 51, 141-154.e6		38
530	Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes. <i>Antibodies</i> , 2019 , 8,	7	12
529	AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. 2019 , 14, 100-112		20
528	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. 2019 , 178, 567-584.e19		64
527	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. 2019 , 216, 2331-2347		9
526	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. 2019 , 4, 31		23
525	Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. 2019 , 16, 31		4

524	Engineering of a Lectibody Targeting High-Mannose-Type Glycans of the HIV Envelope. 2019 , 27, 2038-2052		12
523	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. 2019 , 11,		20
522	Fc Mediated Activity of Antibodies. 2019 ,		1
521	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. 2019 , 6, e667-e679		33
520	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019 , 15, e1008026	7.6	33
519	Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. 2019 , 6, e788-e799		53
518	Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice. 2019 , 47, 247-256		4
517	Effect of diversity in gp41 membrane proximal external region of primary HIV-1 Indian subtype C sequences on interaction with broadly neutralizing antibodies 4E10 and 10E8. 2019 , 273, 197763		4
516	Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. 2019 , 51, 724-734.e4		5
515	An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes. 2019 , 50, 520-532.e3		42
514	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. <i>Frontiers in Immunology</i> , 2018 , 9, 3163	8.4	13
513	Concomitant Enhancement of HIV-1 Replication Potential and Neutralization-Resistance in Concert With Three Adaptive Mutations in Env V1/C2/C4 Domains. 2019 , 10, 2		3
512	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. 2019 , 50, 1513-1529.e9		39
511	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. 2019 , 216, 2071-2090		14
510	The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes. <i>PLoS Computational Biology</i> , 2019 , 15, e1007056	5	12
509	HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions. 2019 , 11,		10
508	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. 2019 , 25, 873-883.e5		25
507	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. <i>PLoS Pathogens</i> , 2019 , 15, e1007819	8.19	12

506	Nanoscale integration of single cell biologics discovery processes using optofluidic manipulation and monitoring. <i>Biotechnology and Bioengineering</i> , 2019 , 116, 2393-2411	4.9	11
505	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. 2019 , 27, 2426-2441.e6		20
504	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019 , 14, e0215163	3.7	25
503	B cells engineered to express pathogen-specific antibodies protect against infection. 2019 , 4,		42
502	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. 2019 , 6, e297-e306		46
501	Antigen-Specific Single B Cell Sorting and Monoclonal Antibody Cloning in Guinea Pigs. 2019 , 10, 672		12
500	Protect, modify, deprotect (PMD): A strategy for creating vaccines to elicit antibodies targeting a specific epitope. 2019 , 116, 9947-9952		22
499	Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. 2019 , 59, 49-56		15
498	Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States. <i>Journal of Virology</i> , 2019 , 93,	6.6	7
497	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. 2019 , 4, 734-747		89
496	Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. 2019 , 6, e230-e239		51
495	The chaperone ERp29 is required for tunneling nanotube formation by stabilizing MSec. 2019 , 294, 7177-7193		12
494	Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus. 2019 , 164, 1297-1308		0
493	Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope. 2019 , 2019, 9804584		2
492	Structural Vaccinology for Viral Vaccine Design. 2019 , 10, 738		32
491	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. <i>Journal of Virology</i> , 2019 , 93,	6.6	10
490	Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming. <i>Frontiers in Immunology</i> , 2019 , 10, 435	8.4	37
489	Cis- and trans-factors affecting AID targeting and mutagenic outcomes in antibody diversification. 2019 , 141, 51-103		13

488	The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization. 2019 , 27, 586-598.e6		24
487	IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. <i>Vaccine</i> , 2019 , 37, 2322-2330	4.1	9
486	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. 2019 , 25, 547-553		126
485	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019 , 15, e1006952	5	13
484	Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. <i>Journal of Virology</i> , 2019 , 93,	6.6	5
483	Broadly Neutralizing Antibodies against HIV: Back to Blood. 2019 , 25, 228-240		17
482	Immune Complex Vaccination. 2019 , 423, 95-118		2
481	A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer. 2019 , 10, 873		10
480	Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. <i>PLoS Pathogens</i> , 2019 , 15, e1007552	7.6	21
479	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. 2019 , 10, 654		18
478	GII.4 Human Norovirus: Surveying the Antigenic Landscape. 2019 , 11,		22
477	Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. <i>PLoS ONE</i> , 2019 , 14, e0212649	3.7	7
476	Improvement of antibody functionality by structure-guided paratope engraftment. 2019 , 10, 721		17
475	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. 2019 , 10,		10
474	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. 2019 , 51, 915-929.e7		62
473	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. 2019 , 11,		2
472	Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector. 2019 , 9, 20005		8
471	Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design. <i>Current Opinion in HIV and AIDS</i> , 2019 , 14, 294-301	4.2	5

470	Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization. <i>Frontiers in Immunology</i> , 2019 , 10, 2968	8.4	26
469	Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. 2019 , 29, 3060-3072.e7		11
468	Strategies for inducing effective neutralizing antibody responses against HIV-1. 2019 , 18, 1127-1143		17
467	HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. 2019 ,		4
466	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. 2019 , 179, 1636-1646.e15		106
465	Coevolution of HIV-1 and broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2019 , 14, 286-293	4.2	6
464	Engineered HIV antibody passes muster. 2019 , 6, e641-e642		1
463	Neutralizing antibodies for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2019 , 14, 318-324	4.2	23
462	An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. 2019 , 162, 118-129		3
461	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. <i>Science</i> , 2019 , 363, 649-654	33.3	138
460	Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time. <i>Journal of Virology</i> , 2019 , 93,	6.6	10
459	An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. <i>Journal of Virology</i> , 2019 , 93,	6.6	27
458	The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses. 2019 , 508, 46-51		3
457	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019 , 27, 196-206.e6	5.2	48
456	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. 2019 , 25, 59-72.e8		56
455	Harnessing Antibody-Dependent Cellular Cytotoxicity To Control HIV-1 Infection. 2019 , 5, 158-176		3
454	Functional and Protective Role of Neutralizing Antibodies (NAbs) Against Viral Infections. 2019 , 83-93		1
453	An Efficient Method to Generate Monoclonal Antibodies from Human B Cells. <i>Methods in Molecular Biology</i> , 2019 , 1904, 109-145	1.4	24

452	Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. 2020 , 18, 402-414		13
451	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020 , 222, 628-636	7	17
450	Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?. <i>Journal of Infectious Diseases</i> , 2020 , 222, 525-527		1
449	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. 2020 , 217,		11
448	Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. 2020 , 8,		10
447	Development of therapeutic antibodies for the treatment of diseases. 2020 , 27, 1		568
446	Cross-Reactivity with Self-Antigen Tunes the Functional Potential of Naive B Cells Specific for Foreign Antigens. 2020 , 204, 498-509		9
445	Broadly neutralizing antibodies and vaccine design against HIV-1 infection. 2020 , 14, 30-42		14
444	The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody. 2020 , 12, 1698128		8
443	Antigen discovery tools for adaptive immune receptor repertoire research. 2020 , 24, 64-70		1
442	Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. 2020 , 53, 548-563.e8		59
441	Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. 2020 , 32, 108122		12
440	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020 , 33, 108322		35
439	Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus. 2020 , 1,		14
438	Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. 2020 , 28, 572-585.e7		27
437	Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. 2020 , 182, 843-854.e12		185
436	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. 2020 , 428, 31-87		
435	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. 2020 , 11, 5850		17

434	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. 2020 , 12, 1836719		3
433	Antibody-guided structure-based vaccines. 2020 , 50, 101428		16
432	Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. 2020 , 68, 325-339		18
431	Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2020 , 11, 583820	8.4	2
430	Cloning antibodies from single cells in pooled sequence libraries by selective PCR. <i>PLoS ONE</i> , 2020 , 15, e0236477	3.7	2
429	Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1. <i>Frontiers in Immunology</i> , 2020 , 11, 1565	8.4	0
428	Human neutralizing antibodies elicited by SARS-CoV-2 infection. 2020 , 584, 115-119		982
427	Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. 2020 , 10, 12995		2
426	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. 2020 , 182, 1295-1310.e20		935
425	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. 2020 , 32, 107981		7
424	Sensitivity to monoclonal antibody 447-52D and an open env trimer conformation correlate poorly with inhibition of HIV-1 infectivity by SERINC5. <i>Virology</i> , 2020 , 548, 73-81	3.6	1
423	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles. <i>Journal of Virology</i> , 2020 , 94,	6.6	8
422	Emerging Concepts and Technologies in Vaccine Development. <i>Frontiers in Immunology</i> , 2020 , 11, 583078.4	8.4	63
421	Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV. 2020 , 19, 285-294		3
420	Conjugation of Native-Like HIV-1 Envelope Trimers onto Liposomes Using EDC/Sulfo-NHS Chemistry: Requirements and Limitations. 2020 , 12,		5
419	Vaccination Strategies Against Highly Variable Pathogens. 2020 ,		
418	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. 2020 , 117, 22920-22931		20
417	A V1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. 2020 , 6,		4

416	CD4 T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy. 2020 , 11,			20
415	Standardized metrics can reveal region-specific opportunities in community engagement to aid recruitment in HIV prevention trials. <i>PLoS ONE</i> , 2020 , 15, e0239276	3.7		5
414	Increased vaccine tolerability and protection via NF- κ B modulation. 2020 , 6,			12
413	Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. 2020 , 5, 72			20
412	Primary HIV-1 and Infectious Molecular Clones Are Differentially Susceptible to Broadly Neutralizing Antibodies. 2020 , 8,			
411	Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission. <i>Journal of Virology</i> , 2020 , 94,	6.6		2
410	Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. <i>PLoS ONE</i> , 2020 , 15, e0232757	3.7		9
409	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. <i>PLoS Pathogens</i> , 2020 , 16, e1008577	7.6		1
408	Factors in B cell competition and immunodominance. 2020 , 296, 120-131			25
407	Tuning environmental timescales to evolve and maintain generalists. 2020 , 117, 12693-12699			17
406	Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 216	5.9		3
405	CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses. 2020 , 8,			3
404	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , 2020 , 369, 956-963	33.3		906
403	Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands. <i>Journal of Virology</i> , 2020 , 94,	6.6		13
402	Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator. 2020 ,			2
401	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. 2020 , 28, 335-349.e6			25
400	A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity. <i>PLoS ONE</i> , 2020 , 15, e0231679	3.7		4
399	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. 2020 , 11,			19

398	Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity. <i>Vaccine</i> , 2020 , 38, 3436-3446	4.1	2
397	Specific Substitutions in Region V2 of gp120 confer SHIV Neutralisation Resistance. 2020 , 9,		1
396	Anti-HIV-1 Antibodies: An Update. 2020 , 34, 121-132		5
395	HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. 2020 , 16, 529-537		20
394	Tunable Fano-Resonant Metasurfaces on a Disposable Plastic-Template for Multimodal and Multiplex Biosensing. 2020 , 32, e1907160		29
393	Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. 2020 , 30, 3964-3971.e7		37
392	Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. 2020 , 117, 7929-7940		2
391	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. 2020 , 27, 531-543.e6		8
390	Combinatorial Resurfacing of Dengue Envelope Protein Domain III Antigens Selectively Ablates Epitopes Associated with Serotype-Specific or Infection-Enhancing Antibody Responses. 2020 , 22, 446-456		1
389	and studies of gp120-HIV-derived peptides in complex with G4-PAMAM dendrimers.. 2020 , 10, 20414-20426		3
388	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. 2020 , 136, 1722-1734		15
387	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. 2020 , 180, 471-489.e22		47
386	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. <i>Structure</i> , 2020 , 28, 897-909.e6	5.2	24
385	Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies. <i>PLoS Pathogens</i> , 2020 , 16, e1008083	7.6	20
384	A Systematic Approach to HIV-1 Vaccine Immunogen Selection. 2020 , 36, 762-770		2
383	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020 , 16, e1007626	5	10
382	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. 2020 , 204, 1543-1561		1
381	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 2020 , 83, 434-439		1

380	Innovations in HIV-1 Vaccine Design. 2020 , 42, 499-514		11
379	openPrimeR for multiplex amplification of highly diverse templates. 2020 , 480, 112752		18
378	Broadly Neutralizing Antibodies for HIV Prevention. 2020 , 71, 329-346		22
377	Targeting the N332-supersite of the HIV-1 envelope for vaccine design. 2020 , 24, 499-509		3
376	Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2020 , 94,	6.6	15
375	Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. <i>Virology</i> , 2020 , 546, 1-12	3.6	3
374	Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. <i>Journal of Virology</i> , 2020 , 94,	6.6	9
373	Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. 2020 , 6, eaaz6225		23
372	Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 176	5.9	9
371	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. 2020 , 27, 963-975.e5		16
370	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , 2020 , 94,	6.6	9
369	Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. 2021 , 44, 7-17		20
368	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021 , 371,	33.3	22
367	Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. <i>Journal of Virology</i> , 2020 ,	6.6	11
366	The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells. 2021 , 54, 235-246.e5		16
365	HIV Gene Therapy: An Update. 2021 , 32, 52-65		5
364	CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts. <i>Journal of Virology</i> , 2021 , 95,	6.6	2
363	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. 2021 , 109, 184-192		3

362	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations.		
361	Broadly neutralizing antibodies for HIV-1 prevention and therapy. 2021 , 51, 101475		7
360	 Rapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations.		0
359	Protective antibodies against human parainfluenza virus type 3 infection. 2021 , 13, 1912884		4
358	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface.		0
357	Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry.		2
356	Therapeutic antibody discovery. 2021 , 417-436		
355	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. 2021 , 13, 1946918		1
354	Encyclopedia of Sustainability Science and Technology. 2021 , 1-30		
353	CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. 2021 , 11, 9009-9021		6
352	Exploring Viral Interference Using Peptides: Molecular Determinants of HIV-1 Inhibition by a Peptide Derived from Human Pegivirus-1 Envelope Protein E2. 2021 , 16, 1290-1296		2
351	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. 2021 , 54, 324-339.e8		15
350	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <i>Journal of Infectious Diseases</i> , 2021 , 223, 22-31	7	4
349	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. 2021 , 64, 103203		7
348	Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial. 2021 , 18, e1003495		14
347	Therapeutic potential of HIV-1 entry inhibitor peptidomimetics. 2021 , 246, 1060-1068		0
346	A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021 ,		47
345	Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. 2021 , 6,		4

344	Prominent Neutralizing Antibody Response Targeting the Glycoprotein Subunit Interface Elicited by Immunization. <i>Journal of Virology</i> , 2021 ,	6.6	4
343	Comparative intravital imaging of human and rodent malaria sporozoites reveals the skin is not a species-specific barrier. 2021 , 13, e11796		5
342	Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. 2021 , 54, 412-436		7
341	Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates. 2021 , 36, 784-795		0
340	A cross-neutralizing antibody between HIV-1 and influenza virus. <i>PLoS Pathogens</i> , 2021 , 17, e1009407	7.6	9
339	Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells.		2
338	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021 , 372,	33.3	217
337	Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. 2021 , 9,		2
336	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. 2021 , 384, 1003-1014		77
335	Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody. 2021 , 118,		7
334	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. 2021 , 35, 108937		1
333	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. 2021 , 54, 769-780.e6		9
332	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. 2021 , 35, 108933		11
331	AIDS in the Heartland-Hemophilia Was the Harbinger of Things to Come. 2021 , 86, 517-522		
330	Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D. 2021 , 9, 612541		4
329	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1916-1924	7	8
328	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. 2021 , 12, 2938		110
327	Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens. 2021 , 103, 052408		3

326	Human Astrovirus 1-8 Seroprevalence Evaluation in a United States Adult Population. 2021 , 13,		1
325	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021 , 12, 678511	8.4	4
324	Sequence and functional characterization of a public HIV-specific antibody clonotype.		
323	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. <i>Frontiers in Immunology</i> , 2021 , 12, 662909	8.4	
322	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. 2021 , 35, 109167		3
321	Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities. 2021 , 18, 12		
320	Structural basis for broad coronavirus neutralization. 2021 , 28, 478-486		65
319	Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. 2021 , 35, 109084		1
318	Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants. 2021 , 18, 17		2
317	Arrangement of VL and VH Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells. 2021 , 1, 26-39		
316	Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein. 2021 ,		
315	Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking. 2021 ,		2
314	Simulation-Based Pharmacokinetics Sampling Design for Evaluating Correlates of Prevention Efficacy of Passive HIV Monoclonal Antibody Prophylaxis. 1-15		1
313	Amping up HIV antibodies. <i>Science</i> , 2021 , 372, 1397-1398	33.3	1
312	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort. 2021 , 35, 2073-2084		
311	Elicitation of neutralizing antibody responses to HIV-1 immunization with nanoparticle vaccine platforms.		
310	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021 , 17, e1009624	7.6	
309	HIV in Neonates and Infants. 2021 , 48, 275-292		1

308	Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Frontiers in Immunology</i> , 2021 , 12, 712122	8.4	2
307	A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. <i>Journal of Virology</i> , 2021 , 95, e0235020	6.6	1
306	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. <i>Frontiers in Immunology</i> , 2021 , 12, 710044	8.4	2
305	Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies. 2021 , 13,		0
304	Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.		
303	Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application. <i>Frontiers in Immunology</i> , 2021 , 12, 697683	8.4	1
302	Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. 2021 , 13,		0
301	CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection. <i>Frontiers in Immunology</i> , 2021 , 12, 708355	8.4	2
300	Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials. 2021 , 26, 219-230		0
299	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. 2021 , 1-10		4
298	The light chain of antibodies specific to the V2 region of HIV-1 can determine their function. 2021 , 82, 923-929		1
297	Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021 , 12, 715464	8.4	4
296	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. 2021 , 36, 109561		2
295	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. <i>Frontiers in Immunology</i> , 2021 , 12, 709994	8.4	0
294	Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer. 2021 , 12, e0127421		1
293	Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding. <i>Journal of Virology</i> , 2021 , 95, e0026821	6.6	2
292	Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01. <i>Frontiers in Immunology</i> , 2021 , 12, 710012	8.4	0
291	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. 2021 , 131,		3

290	Tandem bispecific antibody prevents pathogenic SHIV infection and disease progression. 2021 , 36, 109611	1
289	Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells. 2021 , 6, 113	5
288	Identification of a CD4-binding site-directed antibody with ADCC activity from a chronic HIV-1BLinfected Chinese donor. 2021 , 302, 198470	0
287	Functional and Highly Crosslinkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.	2
286	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. 2021 , 9,	1
285	The unmutated common ancestor of Gp41 conformational epitope targeting variable heavy chain 1-02 utilizing antibodies maintains antibody dependent cell cytotoxicity.	
284	Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies. <i>Vavilovskii Zhurnal Genetiki i Seleksii</i> , 2021 , 25, 562-572	0.9
283	Antigen identification and high-throughput interaction mapping by reprogramming viral entry.	0
282	Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. 2021 , 206, 999-1012	4
281	Current status and future trends of vaccine development against viral infection and disease. 2021 , 45, 7437-7449	2
280	Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations. 2021 , 12,	4
279	Animal models of HIV transmission through breastfeeding and pediatric HIV infection. 2012 , 743, 89-108	5
278	The Influence of HIV Envelope Glycosylation on Adaptive Immune Response. 2014 , 59-83	2
277	Molecular Recognition of HIV Glycans by Antibodies. 2014 , 117-141	5
276	Origin and Evolution of Human Immunodeficiency Viruses. 2015 , 587-611	3
275	Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design. 2019 , 283-298	1
274	Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies. <i>Virology</i> , 2017 , 508, 188-198	3.6
273	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. 2020 , 26, 228-235	30

272	CHAPTER 11:Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. 2017 , 300-357	3
271	Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists. 2016 , 97, 2427-2440	10
270	Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library. 2017 , 98, 791-798	6
269	Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India. 2017 , 98, 1879-1891	14
268	C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. 2013 , 94, 1-19	29
267	Tumor-infiltrating immune repertoires captured by single-cell barcoding in emulsion.	16
266	B cells expressing authentic naïve human VRC01-class BCRs can be primed and recruited to germinal centers in multiple independent mouse models.	1
265	Potent human neutralizing antibodies elicited by SARS-CoV-2 infection.	211
264	Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients.	11
263	Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. 2020 ,	33
262	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. 2020 ,	4
261	Coronacept is a potent immunoadhesin against SARS-CoV-2.	5
260	Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. 2020 ,	40
259	Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates.	2
258	Mechanisms underlying vaccination protocols that may optimally elicit broadly neutralizing antibodies against highly mutable pathogens.	1
257	Structural basis for broad coronavirus neutralization. 2021 ,	14
256	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.	3
255	Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates.	3

254	Susceptibility to Neutralization by Broadly Neutralizing Antibodies Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.		2
253	An HIV-1 broadly neutralizing antibody from a clade C infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses.		2
252	Antibody feedback limits the expansion of cognate memory B cells but drives the diversification of vaccine-induced antibody responses.		1
251	Meeting the Challenge of Vaccine Design To Control HIV and Other Difficult Viruses. 559-570		2
250	Antibodies Targeting the Envelope of HIV-1. 191-208		1
249	Maturation characteristics of HIV-specific antibodies in viremic individuals. 2016 , 1,		30
248	Flow virometric sorting and analysis of HIV quasispecies from plasma. 2017 , 2, e90626		11
247	Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. 2018 , 3,		12
246	Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. 2019 , 129, 850-862		52
245	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. 2020 , 130, 3299-3304		9
244	SIV infection duration largely determines broadening of neutralizing antibody response in macaques. 2020 , 130, 5413-5424		1
243	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 2014 , 124, 1835-43		71
242	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. 2016 , 126, 415-23		50
241	Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency. 2015 , 125, 2271-4		3
240	Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time. <i>PLoS Computational Biology</i> , 2017 , 13, e1005789	5	19
239	Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection. <i>PLoS Computational Biology</i> , 2020 , 16, e1008434	5	2
238	Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. <i>PLoS ONE</i> , 2011 , 6, e23532	3.7	123
237	Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. <i>PLoS ONE</i> , 2012 , 7, e33298	3.7	50

236	Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity. <i>PLoS ONE</i> , 2012 , 7, e37157	3.7	17
235	Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India. <i>PLoS ONE</i> , 2012 , 7, e43704	3.7	10
234	Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection. <i>PLoS ONE</i> , 2012 , 7, e44163	3.7	14
233	Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China. <i>PLoS ONE</i> , 2012 , 7, e47548	3.7	2
232	Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. <i>PLoS ONE</i> , 2012 , 7, e49610	3.7	14
231	CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors. <i>PLoS ONE</i> , 2013 , 8, e53920	3.7	5
230	Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins. <i>PLoS ONE</i> , 2013 , 8, e59803	3.7	7
229	The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. <i>PLoS ONE</i> , 2013 , 8, e68863	3.7	40
228	A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. <i>PLoS ONE</i> , 2013 , 8, e72054	3.7	18
227	Tissue-specific expressed antibody variable gene repertoires. <i>PLoS ONE</i> , 2014 , 9, e100839	3.7	30
226	Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. <i>PLoS ONE</i> , 2014 , 9, e107683	3.7	3
225	Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques. <i>PLoS ONE</i> , 2014 , 9, e114709	3.7	9
224	Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses. <i>PLoS ONE</i> , 2015 , 10, e0119608	3.7	12
223	Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques. <i>PLoS ONE</i> , 2015 , 10, e0120451	3.7	22
222	An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. <i>PLoS ONE</i> , 2015 , 10, e0122443	3.7	13
221	Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop. <i>PLoS ONE</i> , 2015 , 10, e0128823	3.7	9
220	Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection. <i>PLoS ONE</i> , 2017 , 12, e0173577	3.7	4
219	HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site. <i>PLoS ONE</i> , 2017 , 12, e0177863	3.7	9

218	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018 , 13, e0193773	3.7	13
217	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort. <i>PLoS Pathogens</i> , 2016 , 12, e1005369	7.6	178
216	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017 , 13, e1006074	7.6	30
215	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017 , 13, e1006613	7.6	68
214	Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response. <i>PLoS Pathogens</i> , 2017 , 13, e1006614	7.6	28
213	Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. <i>PLoS Pathogens</i> , 2018 , 14, e1006825	7.6	9
212	Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. <i>PLoS Pathogens</i> , 2020 , 16, e1009185	7.6	3
211	Multiplexed CRISPR/CAS9-mediated engineering of pre-clinical mouse models bearing native human B cell receptors. 2021 , 40, e105926		9
210	Prediction of Epitopes of Viral Antigens Recognized by Cytotoxic T Lymphocytes as an Immunoinformatics Approach to Anti-HIV/AIDS Vaccine Design. 2015 , 1,		2
209	Polyvalent AIDS vaccines. 2010 , 8, 622-9		17
208	Lessons learned from HIV vaccine clinical efficacy trials. 2013 , 11, 441-9		27
207	Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1. 2013 , 11, 464-72		4
206	Induction of a Robust Humoral Response using HIV-1 VLP as a Novel Candidate Vaccine in BALB/c Mice. 2019 , 17, 33-41		6
205	Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target. 2020 , 18, 114-131		1
204	Inhibition of HIV-1 Env-Mediated Cell-Cell Fusion by Lectins, Peptide T-20, and Neutralizing Antibodies. 2011 , 5, 44-51		11
203	New templates for HIV-1 antibody-based vaccine design. 2010 , 2, 60		19
202	The challenge of developing universal vaccines. 2011 , 3, 16		11
201	Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine?. 2015 , 2, 183-193		8

200	Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. 2012 , S8, 3			38
199	Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. 2012 , S8,			8
198	Challenges on Induction of Broadly Neutralizing Antibodies for Optimization of HIV Vaccines Development and Vectored Immunoprophylaxis. 2013 , 02, 9-13			1
197	HIV-1 envelope accessible surface and polarity: clade, blood, and brain. 2011 , 6, 48-56			5
196	Variant proteins stimulate more IgM+ GC B-cells revealing a mechanism of cross-reactive recognition by antibody memory. 2018 , 7,			11
195	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. 2019 , 8,			4
194	Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. 2019 , 8,			16
193	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. 2020 , 9,			51
192	To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. <i>Frontiers in Immunology</i> , 2021 , 12, 708227	8.4		2
191	Broadly neutralizing antibodies for the treatment of HIV infection. 2021 , 13, 81-95			0
190	Structures of Two Human Astrovirus Capsid/Neutralizing Antibody Complexes Reveal Distinct Epitopes and Inhibition of Virus Attachment to Cells. <i>Journal of Virology</i> , 2021 , JVI0141521	6.6		0
189	Souped-up antibody fends off HIV.			
188	HIV Life Cycle and Inherited Co-receptors.			
187	[Structural mechanism of immune evasion of HIV-1 gp120 by genomic, computational, and experimental science]. 2011 , 61, 49-57			6
186	Plant-derived anti-HIV-1 proteins. 2011 , 82-93			
185	Encyclopedia of Sustainability Science and Technology. 2012 , 4996-5020			
184	HIV/AIDS Global Epidemic. 2013 , 27-62			
183	[Analytic and integrative perspectives for HIV vaccine design]. 2013 , 63, 219-32			

- 182 Role of HIV Glycans in Transmission and Immune Escape. **2014**, 85-115
- 181 Delivery Strategies for Developing Vaginal DNA Vaccine Combining Cell-Penetrating Peptide and Jet Injection. **2014**, 367-378
- 180 Antigenic Variation?. **2014**, 0
- 179 Genetically Engineered Antibody Molecules. **2014**,
- 178 Antibody-based Protection Against HIV Infection. **2014**, 315-324
- 177 HIV Life Cycle and Inherited Co-Receptors.
- 176 The Immunology of Human Immunodeficiency Virus Infection. **2015**, 1526-1540.e3 1
- 175 Vaccines for Human Immunodeficiency Virus Type 1 Infection. **2015**, 1666-1673.e4
- 174 Antibodies: Computer-Aided Prediction of Structure and Design of Function. 173-190
- 173 Vector-Mediated In Vivo Antibody Expression. 427-440
- 172 High Inter-Individual Diversity of Point Mutations, Insertions, and Deletions in Human Influenza Virus Nucleoprotein-Specific Memory B Cells. *PLoS ONE*, **2015**, 10, e0128684 3-7 2
- 171 HIV Vaccine and Passive Immunity Trials. **2017**, 91-104
- 170 Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples.
- 169 Broad neutralization response in a subset of HIV-1 subtype C-infected viraemic non-progressors from southern India. **2018**, 99, 379-392
- 168 Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine for production.
- 167 Protection of rhesus macaques against vaginal SHIV challenges by VRC01 and an anti-~~47~~ antibody.
- 166 HIV-1 vaccine design through minimizing envelope metastability.
- 165 An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies. 0

- 164 Chimpanzee SIV Envelope trimer: structure and deployment as an HIV vaccine template. 1
- 163 Limitations to the Structure-Based Design of HIV-1 Vaccine Immunogens. **2019**, 143-159
- 162 Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine. **2019**, 163-188
- 161 Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking. **2019**, 103-126
- 160 Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 Not Inform the Rational Design of an HIV-1 Vaccine?. **2019**, 221-228
- 159 Structure-Based Reverse Vaccinology Failed in the Case of HIV Because It Disregarded Accepted Immunological Theory. **2019**, 249-277
- 158 An Outdated Notion of Antibody Specificity Is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. **2019**, 205-216
- 157 Rational design of hepatitis C virus E2 core nanoparticle vaccines.
- 156 Diversity and function of maternal HIV-1-specific antibodies at the time of vertical transmission.
- 155 Functional characterization and lineage analysis of broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics.
- 154 Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques. 1
- 153 Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection. 1
- 152 Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth. 1
- 151 Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.
- 150 Site-specific Labeling of B Cell Receptor and Soluble Immunoglobulin. **2020**, 10, e3767
- 149 Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. **2020**, 3639618 3
- 148 Limited evolution despite years of measurable viremia in a cART-treated seronegative HIV-1 positive individual.
- 147 Pre-existing resistant proviruses can compromise maintenance of remission by VRC01 in chronic HIV-1 infection.

146	A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: effects on glycosylation and antigenicity.	
145	Vaccine Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells.	1
144	CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021 , 12, 757811	8.4
143	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. 2021 , 37, 109922	1
142	A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1. 2021 , 12, 6464	1
141	Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces. 2021 , 12, 6470	1
140	Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can be Minimized by Distant State 1-Stabilizing Changes.	1
139	SOSIP trimer-specific antibodies isolated from a SHIV-infected monkey with versus without a pre-blocking step with gp41. <i>Journal of Virology</i> , 2021 , JVI0158221	6.6
138	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.	
137	A derivative of the D5 monoclonal antibody that targets the gp41 N-heptad repeat of HIV-1 with broad tier-2 neutralizing activity.	1
136	The fusion peptide proximal region of the HIV-1 envelope glycoproteins regulates exposure of immunogenic epitopes at the trimer base.	
135	Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.	
134	Rational design of vaccines for AIDS and influenza. 2012 , 123, 9-15; discussion 15-6	5
133	Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response. 2015 , 7, 11-21	10
132	Neutralization and beyond: Antibodies and HIV-1 acquisition. 2018 , 15, 73-86	1
131	Vectored antibody gene delivery restores host B and T cell control of persistent viral infection. 2021 , 37, 110061	0
130	Broadly neutralizing monoclonal antibodies for HIV prevention. 2021 , 24 Suppl 7, e25829	1
129	Sequence and functional characterization of a public HIV-specific antibody clonotype.. 2022 , 25, 103564	0

128	Protein engineering strategies for rational immunogen design.. 2021 , 6, 154		3
127	So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.. 2022 , 14,		0
126	Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity.. 2022 , 119,		1
125	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. 2022 , 38, 110199		3
124	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. <i>Journal of Virology</i> , 2021 , JVI0134321	6.6	1
123	Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.. 2022 , 13, 630		1
122	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.. 2022 , 13, 732		1
121	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron.. 2021 ,		14
120	HIV vaccines: progress to date. 2011 , 71, 387-414		35
119	HIV-1 Vpu restricts Fc-mediated effector functions in vivo.		0
118	Analysis of B cell receptor repertoires reveals key signatures of systemic B cell response after SARS-CoV-2 infection. <i>Journal of Virology</i> , 2021 , JVI0160021	6.6	2
117	Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.. <i>Journal of Virology</i> , 2022 , e0220121	6.6	1
116	Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings.		1
115	Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.. <i>Journal of Virology</i> , 2022 , e0166821	6.6	2
114	Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.. 2022 , 10,		0
113	CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer.		
112	Multiple gene expression in plants using MIDAS-P, a versatile type II restriction-based modular expression vector.. <i>Biotechnology and Bioengineering</i> , 2022 ,	4.9	0
111	Antibody-dependent cellular cytotoxicity (ADCC) responses along with ADCC susceptibility influence HIV-1 mother to child transmission.. 2022 ,		0

110	First-in-human immunoPET imaging of HIV-1 infection using Zr-labeled VRC01 broadly neutralizing antibody.. 2022 , 13, 1219		3
109	Small-molecule HIV-1 entry inhibitors targeting the epitopes of broadly neutralizing antibodies.. 2022 ,		
108	Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.. <i>Journal of Virology</i> , 2022 , e0187821	6.6	1
107	High-Throughput B Cell Epitope Determination by Next-Generation Sequencing.. <i>Frontiers in Immunology</i> , 2022 , 13, 855772	8.4	0
106	Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice.. 2022 , 3, 101180		
105	HIV-1 CD4-binding site germline antibodyEnv structures inform vaccine design.		1
104	HIV-1 infections with multiple founders associate with the development of neutralization breadth.. <i>PLoS Pathogens</i> , 2022 , 18, e1010369	7.6	1
103	Antigen identification and high-throughput interaction mapping by reprogramming viral entry.. 2022 ,		0
102	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2.. 2022 , 101819		0
101	Sendai virus particles carrying target virus glycoproteins for antibody induction.. <i>Vaccine</i> , 2022 ,	4.1	0
100	Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.		
99	[Protection against HIV-1 infection: "It's the neutralizing antibody, stupid!"]. <i>Medecine/Sciences</i> , 2021 , 37, 1178-1179		
98	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.. <i>Frontiers in Immunology</i> , 2021 , 12, 670561	8.4	0
97	Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.. <i>Cells</i> , 2021 , 11,	7.9	
96	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site.. <i>Structure</i> , 2022 ,	5.2	1
95	An exploration of how broadly neutralizing antibodies might induce HIV remission: the IvaccinaL effect.. <i>Current Opinion in HIV and AIDS</i> , 2022 , 17,	4.2	0
94	Table_1.DOC. 2018 ,		
93	Data_Sheet_1.PDF. 2020 ,		

92 Image_1.TIF. **2020**,

91 Image_2.TIF. **2020**,

90 Image_3.tiff. **2020**,

89 Image_4.TIF. **2020**,

88 Image_5.TIFF. **2020**,

87 Image_6.TIFF. **2020**,

86 Image_1.TIF. **2019**,

85 Image_2.TIF. **2019**,

84 Image_3.TIF. **2019**,

83 Image_4.TIF. **2019**,

82 Table_1.XLSX. **2019**,

81 Table_2.XLSX. **2019**,

80 Table_3.XLSX. **2019**,

79 Table_4.XLSX. **2019**,

78 data_sheet_1.DOCX. **2018**,

77 Presentation_1.PDF. **2018**,

76 DataSheet1.pdf. **2018**,

75 Model systems of human immunodeficiency virus (HIV-1) for in vitro efficacy assessment of candidate vaccines and drugs against HIV-1.. *Vavilovskii Zhurnal Genetiki i Selekcii*, **2022**, 26, 214-221

0.9 1

74	Comprehensive Assessment of Host Cell Protein Expression after Extended Culture and Bioreactor Production of CHO Cell Lines.. <i>Biotechnology and Bioengineering</i> , 2022 ,	4.9	0
73	A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.. <i>PLoS Pathogens</i> , 2022 , 18, e1010488	7.6	
72	Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.. <i>PLoS Pathogens</i> , 2022 , 18, e1010531	7.6	1
71	Production of Recombinant Proteins in Transgenic Tobacco Plants. <i>Methods in Molecular Biology</i> , 2022 , 17-48	1.4	1
70	Contribution of Rare Mutational Outcomes to Broadly Neutralizing Antibodies. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022 ,	2.8	0
69	Antibody Light Chains: Key to Increased Monoclonal Antibody Yields in Expi293 Cells?. <i>Antibodies</i> , 2022 , 11, 37	7	
68	Combination of IM-Based Approaches to Unravel the Coexistence of Two Conformers on a Therapeutic Multispecific mAb. <i>Analytical Chemistry</i> ,	7.8	3
67	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022 , 17, e0268767	3.7	1
66	Futurology and monitoring in the field of virology to deal with emerging diseases. 2022 , 125, 253-263		
65	Learning the statistics and landscape of somatic mutation-induced insertions and deletions in antibodies. <i>PLoS Computational Biology</i> , 2022 , 18, e1010167	5	0
64	HIV-Associated Alterations of the Biophysical Features of Maternal Antibodies Correlate With Their Reduced Transfer Across the Placenta. <i>Journal of Infectious Diseases</i> ,	7	0
63	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> ,	64.1	5
62	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. <i>PLoS Pathogens</i> , 2022 , 18, e1010574	7.6	
61	Commonly Elicited Antibodies against the Base of the HIV-1 Env Trimer Guide the Population-Level Evolution of a Structure-Regulating Region in gp41. <i>Journal of Virology</i> ,	6.6	
60	Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2. <i>Vaccine</i> , 2022 , 40, 4174-4181 ¹	4.1	1
59	Efficient isolation of rare B cells using next-generation antigen barcoding.		0
58	Re-burying Artificially Exposed Surface of Viral Subunit Vaccines Through Oligomerization Enhances Vaccine Efficacy. <i>Frontiers in Cellular and Infection Microbiology</i> , 12,	5.9	
57	Cross-Protective Antibodies Against Common Endemic Respiratory Viruses.		

56	Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naïve and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors. <i>Journal of Medical Virology</i> ,	19.7
55	Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates.	
54	Determining probabilities of HIV-1 bNAb development in healthy and chronically infected individuals.	1
53	Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses. <i>Virology</i> , 2022 , 574, 1-8	3.6
52	Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses.	0
51	Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.	3
50	Antibodies from primary humoral responses modulate the recruitment of naïve B cells during secondary responses. 2022 ,	2
49	A trispesific Ab directed to HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.	
48	A 33-residue peptide tag increases solubility and stability of Escherichia coli produced single-chain antibody fragments. 2022 , 13,	
47	A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. 2022 , 8,	1
46	Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. 2022 , 13,	1
45	Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model. 2022 , 25, 105085	0
44	Development and characterization of a panel of anti-idiotypic antibodies to 1C10 that cross-neutralize HIV-1 subtype B viruses. 2,	0
43	Implications of the 375W mutation for HIV-1 tropism and vaccine development.	0
42	CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.	0
41	Immunization with HIV-1 trimeric SOSIP.664 BG505 or Founder Virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits. 2022 , 100222	0
40	Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. 2022 , 100780	1
39	Engineering the N-glycosylation pathway of <i>Nicotiana tabacum</i> for molecular pharming using CRISPR/Cas9. 13,	0

- 38 SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations. ○
- 37 Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo. ○
- 36 Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. **2022**, 105193 1
- 35 Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus. **2022**, 13, ○
- 34 HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. **2022**, 19, 1
- 33 HIV-1 neutralization tiers are not relevant for inhibitors targeting the pre-hairpin intermediate. ○
- 32 HIV-1 CD4-binding site germline antibody Env structures inform vaccine design. **2022**, 13, ○
- 31 Validation of antigen tetramers for the detection of antigen-specific B cells. ○
- 30 Humanized V(D)J-rearranging and TdT-expressing Mouse Vaccine Models with Physiological HIV-1 Broadly Neutralizing Antibody Precursors. ○
- 29 Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens. **2022**, 18, e1010624 ○
- 28 The applications of machine learning in HIV neutralizing antibodies research: a systematic review. **2022**, 134, 102429 ○
- 27 HIV Co-Receptor Usage, Broadly Neutralising Antibodies, and Treatment. 117-125 ○
- 26 Kennedy epitope (KE)-dependent retrograde transport of efficiently cleaved HIV-1 envelopes (Envs) and its effect on Env cell surface expression and viral particle formation. ○
- 25 Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. ○
- 24 HIV-1 Vpu restricts Fc-mediated effector functions in vivo. **2022**, 41, 111624 ○
- 23 Signatures of VH1-69-derived hepatitis C virus neutralizing antibody precursors defined by binding to envelope glycoproteins. ○
- 22 Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer. **2022**, 18, e1010945 ○
- 21 Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies. 13, ○

- 20 Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?. **2022**, 75, S530-S540 ○
- 19 Indirect Mechanisms of HIV-1 Evasion from Broadly Neutralizing Antibodies In Vivo. ○
- 18 Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles. ○
- 17 Time-resolved single virus tracking and spectral imaging to understand HIV-1 entry and fusion. ○
- 16 Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings. 13, ○
- 15 Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry. **2023**, 28, 474 2
- 14 Characterization of a VRC01-like antibody lineage with immature VL from an HIV-1 infected Chinese donor. **2023**, 154, 11-23 ○
- 13 Broadly Neutralizing Antibody Epitopes on HIV-1 Particles are exposed after Virus Interaction with Host Cells. ○
- 12 Efficient isolation of rare B cells using next-generation antigen barcoding. 12, ○
- 11 Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates. **2023**, 14, ○
- 10 Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis. **2023**, 65, 108143 ○
- 9 Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. **2023**, 15, ○
- 8 HIV/AIDS Global Epidemic. **2023**, 221-250 ○
- 7 CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals. **2023**, 8, ○
- 6 Cross-protective antibodies against common endemic respiratory viruses. **2023**, 14, ○
- 5 An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1. **2023**, 8, 7252-7261 ○
- 4 Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles. **2023**, 97, ○
- 3 LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity. **2023**, 18, e0282147 ○

2 Leveraging deep learning to improve vaccine design. **2023**, ○

1 Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. ○